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4THE NOTCH GENE FAMILY
INTRODUCTION
The Notch signaling is one of the fundamental pathways that regulate metazoan
development and adult tissue homeostasis, that is highly conserved in evolution
throughout the animal kingdom. Thomas Hunt Morgan first described notches at
the margin of wing blades of fruit flyes (Drosophila Melanogaster).1 These
notches were found to be the result of a partial loss of function (haplo-
insufficiency) of the Notch gene encoding for a single transmembrane receptor
that was cloned almost 70 years later as Drosophila Notch.2-3 Notch receptors
and their corresponding ligands play a key role in the development of
multicellular organisms, as they control cell fate by regulating cell proliferation,
survival, positioning in the organism, and differentiation.4 Notch signaling is
also important in adults, in which it regulates stem-cell manteinance, binary cell
fate decisions, such as the T or B-lymphocyte lineage decision, and
differentiation in self renewing organs.5 Drosophila has one Notch receptor
activated by two different transmembrane bound ligands, called Serrate and
Delta, while Caenorhabditis elegans contains two receptors (Glp-1 and Lin-12)
and two ligands (Apx-1 and Lag-2). In contrast, the mammalian Notch family
consists of four highly conserved transmembrane receptors (Notch-1, 2, 3 and
4),6-10which can interact with at least five Notch ligands: Jagged1 and Jagged2
(homologues of Serrate) and Delta-like 1,3 and 4 (homologues of Delta).11-15
5OVERWIEW OF NOTCH SIGNALING PATHWAY
The Notch signaling pathway is complex and involves the coordinated activities
of many different molecules. Notch proteins are membrane-bound type I
receptors (with a single-pass transmembrane domain), harboring a large
extracellular domain involved in ligand binding, and a cytoplasmatic domain
involved in signal transduction. The extracellular domain contains between 29
and 36 epidermal growth factor-like (EGF) repeats, that are critical for binding
interactions with ligand DSL (Delta, Serrate, Lag-2) domains,16-17followed by
three cysteine-rich Notch/Lin-12 (LNR) repeats, that prevent signaling in the
absence of ligand. The intracellular domain of Notch receptors (NICD), which
conveys the signal to the nucleus, harbors several protein-protein interaction
domains such as the RAM23 domain18 and six ankyrin/CDC10 repeats,19which
bind downstream effector molecules, two nuclear localization signals (NLS),
and a PEST sequence [rich in proline (P), glutamic acid (E), serine (S) and
threonine (T)] that negatively regulates protein stability.20  While Notch1 and
Notch2 also contain a transcriptional transactivation domain (TAD), such
domains have not yet been described for Notch3 and Notch4. The Notch
receptors are synthesized as single precursor proteins. O-fucosyltransferase1
(OFUT1) functions as a chaperone and is required for the transport of pre-Notch
from the endoplasmic reticulum (ER) to the Golgi apparatus and for
fucosylation of glycosylated serine and threonine residues of the extracellular
domain in the Golgi.21   
Glycosylation of these residues is carried out by members of the Fringe family
(radical, manic and lunatic), and this modification is important because it affects
6sensitivity to the ligands.22-24 A Furin-like convertase cleaves pre-Notch into the
extracellular and intracellular domain (S1 cleavage), which results in a
heterodimeric receptor with non-covalently associated domains that is
transported to the plasma membrane.25-26 Notch signaling initiates through
ligand-receptors interactions between neighboring cells, leading to two
consecutive proteolytic cleavages of the receptor (S2 and S3), which ultimately
liberate NICD. After ligand binding the ubiquitin ligases mind bomb27-28 or
neuralized29-31 interact with the ligand intracellular domain to promote its
ubiquitination and internalization. Ligand endocytosis leads to a conformational
change in Notch that allows ADAM (metalloprotease and disintegrin) protease
TACE (tumor-necrosis factor α-converting enzime) to cleave the receptor at a
second site (S2) on the extracellular side, close to the transmembrane domain.32
The extracellular Notch domain is then transendocytosed by the ligand-
expressing neighboring cell.33 S2 cleavage determines a conformational change
that allows access of the γ-secretase complex, whose key components are
presenilin and nicastrin, which is responsible for the second proteolytic cleavage
(S3) that occurs in the transmembrane domain and liberates the intracellular
domain (NICD).34-36 Then, NICD translocates to the nucleus where it binds
through its RAM23 domain to the transcription factor CSL (CBF1 in humans,
RBP-Jκ in mice, Suppressor of Hairless in Drosophila, Lag1 in C. Elegans). In
the absence of Notch activity, CSL proteins bind to promoters of its target genes
and recruit histone deacetylases37 and corepressors, as SMRT/Ncor and
SHARP/MINT, that inhibit transcription.38 The NICD/CSL interaction converts
CSL from a transcriptional repressor into a transcriptional activator by
displacing the corepressor complex and recruiting coactivators, through the
ankyrin repeats of Notch, such as Mastermind-like proteins (MAML)39-40, which
7in turn recruit additional coactivators such as histone acetyltransferase
CBP/P300.41-43
To date only a few  Notch target genes have been identified, some of which are
utilized in multiple tissues while others seem to be tissue specific. The best
known Notch target genes are members of the basic helix-loop-helix family such
as HES1 and HES544, the related HERP (HES-related repressor protein)
transcription factor family45, the cell cycle regulator p2146, Nrarp (notch-
regulated ankyrin repeat protein)47, Deltex148, and the pre-T cell receptor-α
gene.49 An additional level of complexity derives from the fact that Notch
signaling can be regulated by several modulators that act at extracellular,
cytoplasmic or nuclear levels. Besides Fringe, described above, which acts at
extracellular level, examples of cytoplasmic modulators of notch signaling
include Numb and Deltex. Numb suppresses Notch signaling, possibly by
preventing nuclear localization and targeting NICD for degradation  through the
E3 ligase Itch.50-51 Deltex is a positive regulator of Notch in Drosophila52 but can
inhibit Notch signaling in mammals.53 An alternative CSL-independent pathway
has been described in which Notch signaling is mediated through Deltex.54
Examples of nuclear modulators are Nrarp and MINT(Msx2-interacting nuclear
target protein) both of which seem to negatively regulate Notch signaling. It is
currently unknown how Nrarp inhibits Notch signaling55, whereas MINT has
been shown to compete with NICD for binding to CSL.56 The stability of
nuclear NICD is regulated through its PEST domain. Binding of MAML to p300
and cyclin-dependent kinase 8 (CDK8) promotes hyperphosporylation of the
NICD PEST domain to facilitate ubiquitylation, probably by members of the
SEL1 (also known as FBW7) family of E3 ligases and the Itch E3 ligase, which
target NICD to the proteasome.57-58
8NOTCH IN HEMATOPOIETIC AND LYMPHOID
DEVELOPMENT
The notch pathway is gaining increasing recognition as a key regulator of
developmental choices, differentiation and function throughout the
hematolymphoid system. Notch controls the generation of hematopoietic stem
cells during embryonic development and may affect their subsequent
homeostasis. Commitment to the T cell lineage and subsequent stages of early
thymopoiesis is critically regulated by Notch. The Notch pathway is linked to
early hematopoiesis during embryonic development and to the control of
hematopoietic stem cell (HSC) self-renewal. Notch1 plays a critical role in the
generation of the earliest embryonic HSCs required for definitive
hematopoiesis.59 Hirai’s group59 found a marked impairment in the ability of
Notch1-/- embryos to generate hematopoietic colonies from structures including
the aorta-gonad-mesonephros region, an important site of early hematopoietic
activity where HSCs likely arise from hemangioblast precursors. Reconstitution
of conditioned newborn recipients was defective, strongly suggesting a defect in
HSC numbers or function. Importantly, Notch1 seemed critical during a narrow
time window, after which the HSC pool could be maintained without Notch. The
molecular mechanisms by which Notch controls the generation of embryonic
HSCs is unknown, but the effect is cell autonomous.60 Interactions with other
key factors in this process, such as LMO2, GATA-2, AML1, and SCL/Tal-1,
need to be explored.
Ligand-mediated Notch stimulation, or expression of constitutively active forms
of Notch, can promote self-renewal of adult HSC.61-63 Recent data suggest that
9osteoblasts, a critical cell type in HSC niches, upregulate Jagged1 when
activated by parathyroid hormone (PTH) or PTH-related protein, which may
activate the Notch pathway in resident HSCs.64 However, it is unclear if this
translates into a physiological role for Notch in the maintenance of HSCs. To
date, no genetic models of Notch inactivation have shown clearcut evidence for
such a role. In particular, bone marrow (BM) from conditional Notch1 or
CSL/RBP-J knockout mice can compete with wild-type BM in trilineage
hematopoiesis of mixed BM chimeras, which is strong evidence against a major
HSC deficiency in the absence of Notch1 or CSL/RBP-J.65-66 More definitive
answers may come from careful studies of HSC function in genetic models of
Notch inactivation, including systems in which CSL/RBP-J-independent
activities can be blocked. Because HSC self-renewal is controlled through
multiple pathways, it is critical to understand the relative importance and
interactions of Notch and other factors, such as Wnt, HoxB4, and Sonic
Hedgehog.91-92-93
NOTCH AND T CELL DEVELOPMENT
The development of mature T cells from lymphoid progenitor cells involves a
series of cell fate choices and differentiation steps that direct cells along one of
several distinct developmental pathways. T cell development occurs in the
thymus, a multi-lobed organ composed of cortical and medullary areas
surrounded by a capsule. T cell precursors enter the subcapsular cortical areas,
where they encounter networks of cortical epithelial cells, the thymic stroma,
and undergo a period of proliferation. As they differentiate, they move from the
cortex towards the medulla of the thymus. Hematopoietic stem cells, just arrived
in the thymus, begin to express CD2, but have not yet rearranged their genes for
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T cell antigen receptor (TCR), are negative for the expression of CD3, and
finally they lack markers typical of mature T cells, (CD4 and CD8), for this
reason they are defined double negative thymocytes (DN or CD4-CD8- ), the
most immature subpopulation of T cells. A small amount of double negative
thymocytes, about 5%, express TCRγδ on the membrane, the majority are
committed to become mature αβ T cells. Depending on the expression of two
markers on the mebrane, the adhesion molecule CD44, and the α chain of the
IL-2 receptor, also known as CD25, DN thymocytes can be classified in four
subpopulation: CD44+CD25–(DNI), CD44+CD25+(DNII), CD44–CD25+(DNIII),
CD44–CD25– (DNIV). First, αβ  T cells express CD44, then CD25.
CD44lowCD25+ double negative T cells rearrange TCRβ  chain. β  chain
rearrangement begins with D-J joining, followed by V-DJ joining. Only DN
thymocytes that have successfully rearranged β chain survive, the others
undergo apoptosis and die. Productive rearrangement of β chain is followed by
its expression on the T cell membrane with CD3 and surrogate α chain, pTα,
forming the pre-T cell receptor complex (preTCR). Signaling through the
preTCR causes the cells to stop rearranging β chain, undergo a period of  intense
proliferation, and begin to express both CD4 and CD8, becoming double
positive T cells (DP or CD4+CD8+). Membrane CD25 is lost at this stage, and
DP cells express again RAG-1 and RAG-2 to rearrange their α chain genes. At
this point DP αβ TCRlow cells move into the cortico-medullary junction, where
they undergo positive and negative selection, two processes fundamental for
establishing immunity and self-tolerance, and mature into single positive T cells
(CD4+ or CD8+).
Proliferation, cell fate specification or death of T cell progenitors is determined
by intrathymic instructive and permissive signals, that are either cell
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autonomous or arise from interactions with the thymic stroma and direct the
thymocyte progression from immature CD4-CD8- double negative (DN) towards
CD4+CD8+ double positive (DP) phenotype and their CD4+CD8- versus CD4-
CD8+ single positive (SP) cell lineage choice. These signals include those
generated by T cell specific differentiation products, i.e. pre-T cell receptor
(TCR) and mature αβ TCR.70-71
T cell development is also controlled by general biological regulators, including
Notch receptors. Indeed, an expression profile description of components of the
Notch signaling pathway (Notch family gene members and their cognate ligands
and target genes) has been provided for the thymus.72 More specifically, Notch1
expression is high in early DN thymocytes, low in DP cells and intermediate in
CD4 and CD8 SP cells.53,73 Interestingly, unlike Notch1, Notch3 expression
window takes place in DN thymocytes at the CD44-/CD25+ DN3 stage, and is
down-regulated before the transition to DP cells to reach very low levels in
mature T lymphocytes.72,74
The presence of multiple Notch receptors and their differential expression along
the different developmental steps raise the question of whether different such
receptors play distinct roles during thymocyte differentiation. In particular,
Notch1 and Notch3 have been related to distinct steps of T cell differentiation
program, from the initial specification of T cell lineage precursors, at an early or
prethymic stage, until the final decision of thymocytes to become CD4+ or CD8+
lymphocytes.75A significant role for Notch1 has been suggested in the initial T
cell lineage commitment of bone marrow-derived common lymphoid
precursors76,77  and in intrathymic differentiation of T lymphoid cell lineages, by
favoring αβ versus γδ T cell lineage decision78,79 as well as in thymocyte
survival and protection against glucorticoid- and TCR-induced apoptosis.80,81
More recently it has been shown that Notch1 is required for a correct VDJβ
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rearrangement.82 Still debated, instead is the role in the CD8 versus CD4 T cell
lineage decision. The best-established function of Notch1 during lymphoid
development is its role in T lineage commitment. As first shown by Radtke’s
group, Notch1’s loss of function results in a marked decrease in the size of the
thymus that lacks T cells and contains an excess of B cells.65-66 These B cells
resemble BM B cells and develop intrathymically.83 Conversely, expression of
constitutively active Notch1 in HSCs results in extrathymic T cell development
and suppression of BM B cell development.84 In culture, expression of Notch
ligands of the Delta-like family (Dll-1 or Dll-4) in BM stromal cell lines is
sufficient to drive multipotent hematopoietic progenitors, or even embryonic
stem cells, to the T cell lineage, while suppressing B cell development.84-
87Notch1 inactivation causes a complete block in T lineage development,
indicating that other Notch family members cannot compensate for the loss of
Notch1 in vivo.66 The distinctive functions of Notch family members could be
related to the activation of different downstream signals or to a variable binding
efficiency with different Notch ligands.
In terms of the relevant Notch-mediated intracellular signals for T lineage
commitment, conditional inactivation of CSL/RBP-J results in a developmental
block similar to the block observed in Notch1-deficient mice,65,88 indicating that
relevant Notch-dependent signals are mediated by CSL/RBP-J during T cell
commitment. Beyond initial T lineage commitment, developing thymocytes
undergo the decision to become either αβ or γδ lineage T cells. An instructive
model of αβ versus γδ development suggests that the nature of the first
successful T cell receptor (TCR) gene rearrangement dictates the lineage
decision, so that cells first producing a functional β chain together with pre-
TCRα (pTα) commit to the αβ lineage, and cells rearranging both γ and δ genes
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are instructed to the γδ lineage. A role for Notch1 in the αβ versus γδ lineage
decision was first suggested by Robey’s group.78 These investigators generated
mixed BM chimeras with Notch1+/- and Notch1+/+ progenitors.78 In the thymus
of these mice, a decreased proportion of αβ lineage cells was derived from the
Notch1+/– progenitors in competition with the Notch1+/+ cells, whereas the
reduction in γδ T cells was much less dramatic. These data suggest that higher
levels of Notch signaling can favor the αβ lineage. It is unclear from these data
if γδ development is the default cell fate and increasing Notch signaling plays an
inductive role toward the αβ lineage, or if Notch controls a true binary cell fate
decision from a common progenitor. Additional results from Robey’s group and
others indicate that Notch can probably influence γδ versus αβ lineage choice
independently of the expression of pre-TCR or TCRγδ. Indeed, the thymus of
lck-ICN1 transgenic mice showed an increased number of CD8+ TCRγδ+ cells
but not CD4-CD8- TCRγδ+ cells. Lck-ICN1 transgenic mice crossed to a TCRγδ
transgenic strain had a significant increase in CD8TCRγδ+ cells but a decrease in
the percentage of CD4-CD8-TCRγδ+ cells, suggesting that the increased CD8+
TCRγδ+ cells may actually be αβ lineage cells selected through the expression
of TCRγδ. Moreover, expression of transgenic ICN1 in a TCRβ-deficient
background increased the generation of CD4+CD8+ cells expressing TCRγδ with
functional rearrangements at the TCRδ locus, suggesting that Notch could
increase the development of αβ lineage cells even when pre-TCR components
are deficient and αβ lineage cells are selected through the expression of TCRγδ.
Honjo’s group89 reported the phenotype of CSL/RBP-J conditional knockout
mice crossed to lck-Cre, in which the CSL/RBP-J-dependent activity of all four
Notch family members is abolished. The earliest studies examining the role of
Notch signaling in the development of CD4 and CD8 T-cell lineages employed
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transgenic mice expressing an activated form of Notch1 (NotchIC). In these
mice, fewer CD4 SP and more CD8 SP thymocytes were generated. Moreover,
thymocytes recognizing class II MHC could be diverted from the CD4 to the
CD8 lineage, leading to the proposal that Notch plays a role in CD4/CD8
lineage commitment.78 Notably, activated Notch could not bypass the
requirement for MHC-dependent positive selection. In contrast, another group
using a more transcriptionally active transgenic construct concluded that Notch
activity promoted the survival and development of both CD4 and CD8 lineage T
cells and could do so in the absence of MHC recognition.48 This discrepancy
could be related to a difference in propensity to develop tumors. When young
mice were analyzed before tumors arose, activated Notch inhibited CD4 and
promoted CD8 SP thymocyte development in both strains. Moreover,
development of SP thymocytes in both strains was MHC dependent. Although
these gain-of-function studies suggested that forced Notch activity could
influence lineage commitment, the role of endogenous Notch in CD4/CD8 fate
determination remained unresolved. Thymocytes individually deficient in
Notch1, -2, or -3 show no alterations in CD4/CD8 T-cell development. There is
the possibility for functional redundancy among the four Notch homologs, but
analyses of compound Notch deficiencies in thymocytes have not been reported.
Conversely, a specific role of Notch3 at the preTCR checkpoint has been
suggested, since it has been demonstrated a preferential upregulation of Notch3
(compared to Notch1) in DN immature thymocytes prior to their transition to
more mature DP and a subsequent downregulation across the DN to DP
transition.72 These events are controlled by the pre-TCR signalling pathway, and
are characterized by an activated NfkB.90-91 Moreover, Lck promoter-Notch3-IC
transgenic mice display a peculiar phenotype of dysregulated early T cell
development characterized by the significant expansion of CD25+ DN
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thymocyte subsets, the sustained expression of CD25 and pTα invariant chain of
the preTCR and a constitutively activated NFkB in all thymocyte subsets and
peripheral T cells.92 Consistent with the different timing of Notch1 and Notch3
activity during T cell development process, in vivo experimental models
characterized by constitutively active transgenes have shown significant
differences between Notch1 and Notch3 in regulating and/or affecting T cell
development. Indeed, Notch1 is not able to trigger the generation of DP
thymocytes in the absence of a functional preTCR.93 In contrast, Notch3 is able
to rescue the blockage of the pre-TCR check-point by forcing immature DN
thymocytes to progress toward a more differentiated phenotype  (e.g. acquisition
of CD4, CD8 and TCRα expression) in the absence of pTα/preTCR.74 However,
the role of Notch3 in T cell development will be treated in more details below.
NOTCH ACTIVATION IN THE MOLECULAR
PATHOGENESIS OF T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA
T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy of thymocytes
that develops mainly in children and adolescents but also arises in adults, which
constitutes approximately 15-20% of ALL. This aggressive tumor is
characterized by high peripheral blood cell counts, increased numbers of blast
cells, CNS dissemination and large mediastinal masses that cause tracheal
compression and respiratory distress at diagnosis. Altough T-ALL often arises in
the thymus, it spreads throughout the body and, without therapy, is rapidly fatal.
Current treatment for T-ALL consists mainly of multi-agent combination
chemoterapy.94 Leukaemic trasformation of developing thymocytes is caused by
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multistep mutagenesis involving various genetic alterations that shift normal
cells into uncontrolled growth and clonal expansion. These changes can affect
cell cycle control, stem-cell manteinance and cell proliferation, differentiation
and survival. Cytogenetic analyses and the molecular cloning of chromosomal
translocations breakpoints led to the discovery of transcriptional regulatory
proteins that are aberrantly expressed in T-ALL owing to the juxtapositioning of
their respective genes next to strong T-cell receptor (TCR) gene enhancers and
promoters, without alterations in protein structure (with the exception of TAN,
or truncated activated Notch1). In general, these translocated proteins have
important functions during normal embryogenesis, although many are not
essential for the development of normal thymocytes.95 So, many cases of T-ALL
seem to result from the thymocyte specific aberrant expression of proteins that
normally function primarily in non-lymphoid tissues. Aberrant Notch signaling
occupates a central role in the pathogenesis of human T cell acute lymphoblastic
leukemia/lymphoma. Unlike most other genes associated with human T-ALL,
that are not normally expressed in developing T cells, Notch exerts its
trasforming function in the same lineage in which it is most highly expressed.96
In fact, as seen, Notch signaling mediates hematopoietic cell fate determination
in the embryo and in the adult, and consequently deregulated expression of
Notch pathway elements can lead to development of haematological
malignancies. Historically, the first human homologue of Drosophila Notch,
Notch1, was identified at the chromosomal breakpoint of a subset of T cell
lymphoblastic leukemias/lymphomas containing a t(7;9)(q34;q34.3)
chromosomal translocations.96 The traslocation fuses the 3’ portion of Notch1 to
the T cell receptor Jβ locus. The molecular breakpoints in the t(7;9)-associated
tumours all cluster within 100 base pairs of intron 24 of Notch1. So, most of the
extracellular domain is deleted, which results in a series of Notch1 peptides of
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different size, all of which are devoid of EGF repeats and Notch/LIN12 repeats.
These truncated Notch1 isoforms are temporally and spatially expressed in the
manner of the TCRβ locus and most of them possess constitutive, ligand-
independent activity. However this initial discovery did not reveal the full
oncogenic potential of the truncated version of N1ICD. A causative role of
Notch1 in T cell lymphomagenesis was only shown when Pear97 showed in a
murine system that the overexpression of N1ICD using a retroviral transduction
assay of hematopoietic stem cells led to development of highly aggressive
immature T-cell malignancies, reinforcing an immature T cell neoplasms. These
and subsequent studies98-99 provided the initial basis for an experimental model
whereby mutations in Notch1 have been analyzed for their oncogenic potential.
This was shortly followed by studies with transgenic mice expressing dominant
active forms of Notch1,48,78,100 by the identification of additional Notch1
rearrangements in mice with radiation-induced thymomas,101 and Notch1
mutations in murine transgenic models of T-ALL.102Despite the efficiency of
Notch1 in inducing T-ALL in murine models, it became soon clear that the rare
t(7;9) translocation event could account for only  a minor fraction of T-ALL
cases.103 Ellisen et al.96 originally screened 40 T cell leukemia/lymphoma patient
samples and found 4 with the t(7;9) translocation. Based on this, an incidence of
~10 % was estimated. However, in subsequent studies, it appears that <1% of all
human T cell leukemias or lymphomas contain this translocation.103 However,
more importantly, aberrant Notch signaling was subsequently found in several
human leukemias and lymphomas that lacked genomic rearrangements,74,104-105
signifying that upregulated Notch signaling might have a common role in human
leukemogenesis. Jundt et al.104 found high levels of NOTCH1 protein expression
in twelve T cell anaplastic large cell lymphoma (ALCL) samples as compared to
B cell lymphomas, and high levels of cleaved (activated) NOTCH1 were seen in
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two human ALCL-derived cell lines, compared to normal T cells. Definitive
evidence for a central role of Notch1 in human T-ALL came from a recent study
in which somatic activating mutations in Notch1 were found in more than 50%
of human T-ALL samples.106 Moreover, when 30 human T-ALL cell lines were
screened for Notch1 dependency using a γ-secretase inhibitor, five showed a
G0/G1 cell-cycle arrest that could be rescued by viral expresson of the
intracellular domain of notch1 (ICN1). Sequencing of Notch alleles in these cell
lines identified missense mutations at conserved amino-acid positions in the N-
and C-terminal heterodimerization domains, that lead to ligand independent
metalloprotease cleavage at site S2,106 and short insertions or deletions in the
polypeptide enriched in proline, glutamate, serine and threonine (PEST) domain,
resulting in partial or complete deletion of this domain, and consequent
stabilization of ICN1, finally in cis in the same Notch1 allele.  Furthermore,
Screpanti’s lab demonstrated that Notch3 was consistently expressed in 30
human T cell acute leukemias samples, and dramatically reduced levels were
seen at clinical remission.74 Interestingly, in T-ALL, Notch-3 is associated with
the expression of its target gene, HES1, and of the gene encoding pTα.74
Expression of these three genes is normally limited to thymocytes and none is
usually expressed in normal mature peripheral T cells. Thus, a T-ALL signature,
resulting from the combined expression of NOTCH3, pTα  and HES1,
characterizes the active and relapsing disease. N3ICD could possibly function
also by activating NF-kB via its recently described effect on IKKα.107 However,
the role of Notch3 in T-ALL leukemia will be described in details in an another
paragraph. These observations suggest the possibility that up- regulation of
Notch may play a role in more than the small subset of lymphomas that have the
t(7;9) translocation. More compelling evidence was brought about by a study
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published from the laboratory of Aifantis.108 They analyzed the gene expression
profile of primary hematopoietic stem and lymphocyte progenitor cells, as these
are the cell populations where random Notch1 activating mutations initially
occur. The analysis revealed that a panel of significantly up-regulated genes
were components of the NF-kB pathway and included target genes such as
Nfkb2, Relb, Nfkbia, Bcl2a1 and Ccr7. A direct link between the Notch and
NF-kB pathway was provided using N1ICD to induce the activity of NF-kB
reporters. Dominant negative forms of the MAML1 and  IkBa genes,
respectively, could efficiently antagonize these interactions. Conclusive
evidence was provided in the same study showing that NOTCH1 human T-ALL
derived mutations activate the NF-kB pathway and that T-ALL cell lines have
an activated NF-kB pathway. However, the precise mechanism by which Notch1
induces T-ALL is not yet fully elucidated. Several studies published recently
have identified potential Notch target genes that may play a role in the
oncogenic potential of Notch in the development and/or maintenance of disease,
like the transcription factor E2A, the F-box protein SKP2, cyclin D3, p53 and c-
myc.109-113
THE ROLE OF NOTCH3 IN T-CELL DEVELOPMENT AND T-
ALL LEUKEMIA
The presence of multiple Notch receptors raised the question of whether such
different receptors play distinct roles during thymocyte differentiation. Indeed,
we observed previously that a significantly higher percentage of DN thymocytes
express Notch3 relative to Notch1 and that there was a preferential up-regulation
of Notch3 (compared with Notch1) in DN thymocytes prior to their transition to
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the CD4+8+ double positive (DP) stage following interaction with thymic
epithelial cells.72 Most provocatively, Notch3 is down-regulated across the
DN–DP transition that is controlled by the pre-TCR signaling pathway.
To assess the ability of Notch3 to influence T-cell development, Notch3
transgenic mice were generated using the lck proximal promoter to overexpress
a hemagglutinin (HA) epitope-tagged Notch3-IC (Notch3 intracellular domain),
able to trigger ligand-independent Notch3 intracellular signaling.114
Constitutive activation of Notch signaling in Notch3 transgenic mice is
suggested by enhanced expression of specific Notch target genes, such as HES-1
and Deltex.
The thymocyte phenotype of wild-type and tg (transgenic) mice was analyzed at
different ages. Until 4 weeks of age, there was a reproducible increase in the
thymocyte number in tg mice (3.0x108/thymus compared with 1.8x108/thymus
in wild-type 3-week-old mice). Absolute numbers of cells of each subset (DN,
DP and SP) were increased. Although there was no obvious impairment of
thymocyte subset distribution with respect to CD4+ and/or CD8+ cells, most tg
thymocytes, including DN thymocytes, stained brightly for CD3 and TCR. A
higher percentage of tg thymocytes also stained brightly for CD69, mainly
observed in the DP subsets. Thus, overexpression of Notch3-IC alters thymocyte
differentiation. Further evidence of this was provided by the fact that all tg
thymocyte subsets included cells expressing high levels of CD25, broadly
distributed in cortex and medulla of thymus sections. This phenotype might be
interpreted as a failure to down-regulate CD25 expression that occurs ordinarily
in DP and SP subsets after 17–18 days post-conception.115 To examine whether
the increased number of thymocytes was attributable to changes in the earliest
subsets, we examined DN thymocytes, segregated into four subsets (I–IV) based
on the discrete expression of CD44 and CD25.116Both CD25+ DN subsets (II and
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III) were over-represented in tg mice, the latter consistent with a failure to
down-regulate CD25. Ordinarily, the pre-TCR-regulated transition of subset III
(CD44-/CD25+) cells into subset IV (CD44-/CD25-) cells is a critical point in
thymocyte differentiation, as thymocytes are rescued from apoptosis and
induced to expand clonally.117DN cells from tg versus non-tg littermates showed
little increase in the proportion of cells in S + G2-M phases of the cell cycle
(29.0 versus 23.8%, respectively). A noticeably smaller percentage of tg DN
cells were apoptotic compared with wild-type mice (2.4 versus 8.1%,
respectively).
Two transient peaks of NF-κB activity occur in the thymus, one in CD8+ SP
cells and one as cells move through the late DN stages.118-119 We and others
observed that the latter subset-specific NF-κB activity provides relief from
apoptosis as late DN thymocytes proliferate in response to signals from the pre-
TCR.90,119 Given the expansion of late DN thymocytes, the reduced levels of
apoptosis and the sustained expression of a number of previously described NF-
κB target genes, including CD25, IL-2, IFN-γ, IL-4, TNF-α and Bfl-1/A1, in tg
mice120-121 we examined NF-κB activity. Compared with wt mice, nuclear
extracts from thymocytes of 2- to 4-week-old Notch3 tg mice displayed
constitutive high levels of specific p50–p65 NF-κB–DNA complexes. These
data demonstrate that Notch3 promotes NF-κB activation in thymocytes,
consistent with improved survival and increased numbers of thymocytes in
Notch3 tg mice.
One of the most intriguing features of transgenic mice is the overexpression of
both pTα isoforms, a and b, and the persistence of their expression also in
double positive and single positive thymocytes, and moreover in mature
peripheral T cells, where they are not normally expressed.  By mutliple criteria,
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young tg animals appeared normal until 7 weeks of age, at which point all 14
founders and progeny developed a rapidly evolving disease, characterized by
lethargy, hunched posture and distended abdomen. Eighty percent of tg animals
succumbed between 10 and 12 weeks of age, and by 16 weeks 95% of tg mice
had died. By 30 weeks, all mice were sacrificed. Examination of all tg mice
revealed, as early as 5–6 weeks and at all ages thereafter, a significant
enlargement of the upper mediastinum and a 5- to 6-fold increase in the size and
weight of the spleen and peripheral (axillary, cervical and abdominal) lymph
nodes, compared with wt mice. A hyperplastic thymus was also observed in
some tg mice. Histological examination of the thymus, spleen and lymph nodes
showed a complete disruption of the normal architecture and a massive
infiltration by a monotonous lymphoblastic cell population. Tumor cell
infiltration was also detected in liver, lungs, kidney, bone marrow and peripheral
blood, thus indicating the existence of a leukemic phase of the neoplastic
disease. All splenic or lymphonode lymphomas tested and a cell line [N3-232T,
established from the thymocytes of a 6-week-old tg mouse] could be serially
transplanted (20x106 cells injected subcutaneously) and elicited a lethal
infiltration into the lymphoid organs of recipient nude or syngeneic mice, with
latency periods of 2 and 3 weeks, respectively. Moreover, N3-232T cells shared
phenotypic features of the spontaneously arising lymphomas, such as CD3high
(>80% of cells), CD25high (30% of cells), pTα expression and activated NF-κB.
Interestingly, N3-232T cells also displayed the DN phenotype of immature
thymocytes.
Splenic lymphoma cells from three indepedent Notch3 tg lines displayed
variable percentages of CD4 and CD8 expression, ranging from mainly DP to
CD8 SP, suggesting their origin in heterogeneous differentiation stages.
Lymphoma cells closely resembled Notch3 tg thymocytes in their expression of
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CD25, increased in frequency by 10- to 20-fold compared with spleen cells of
normal mice. This evident parallel between the lymphomas and the dysregulated
thymocyte development seen in younger tg mice suggested that other early
thymocyte markers might also be retained aberrantly in the periphery of the tg
mice. Indeed, tg spleen cells showed sustained expression of both pTα isoforms,
a and b,122not normally expressed in mature peripheral T cells.
In conclusion, in this study we demonstrated that the expression of a
constitutively active form of Notch3 in transgenic mice leads to specific
alterations in thymocyte development that are sustained in the outgrowth of
aggressive T-cell lymphoblastic lymphomas by 6 weeks of age. The specific
altered thymocyte phenotype, particularly the persistence of CD25 and pTα
expression and activation of NF-κB, and their sustained expression in tumors,
suggests that late DN T cells are the initial target of Notch3-induced
dysregulation, and that such early dysregulation may constitute the platform for
subsequent lymphomagenesis, albeit in parallel with further differentiation, and
indicated a novel and particular role for Notch3 in coordinating growth and
differentiation of thymocytes, across double negative to double positive
transition, consistent with the normal expression pattern of Notch3. To study
whether the presence of Notch3-associated dysregulation of T cell development
at the preTCR stage might also occur in human T-ALL, we have investigated the
expression of Notch3 and pTα in a series of T-ALL samples. Thirty cases of T-
ALL were examined by RT-PCR and Northern blot for the expression of
Notch3, Notch1, and both forms of pTα mRNA. Expression of Notch3 and both
forms of pTα was revealed by both RT-PCR and Northern blot analysis in all
cases of T-ALL investigated, irrespective of the immunophenotypic and
cytogenetic subclassification of the tumor. Notch1 expression was also usually
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observed in T-ALL; however, unlike Notch3, Notch1 expression was not
pathognomonic for T-ALL, because Notch1 was generally detected not only in
normal peripheral blood T lymphocytes but also in non-T cell leukemias.
To examine further the association of Notch3 and pTα expression in human T-
ALL and the state of the disease, bone marrow samples at different stages of the
disease were examined. The remission stage was distinguished from active
disease by barely detectable levels or absence of both Notch3 and HES-1
expression, suggesting the activation of Notch3 signaling in active disease. pTα
expression was also decreased dramatically in remission samples, and extensive
analyses showed that the most reproducible distinguishing feature was the
expression of the pTα b transcript, which may represent a more sensitive
indicator of the gene expression.127
The lymphomagenic potential of Notch3 overexpression in vivo has been
reported.101 The combined expression of Notch3 and pTα in human T-ALL and
their absence in remission, in normal peripheral T cells and in non-T cell
lymphomas, as reported here, suggested a link between Notch3 signaling
pathway activation and pTα expression in human T-ALL. To investigate the
relationship between Notch3 expression, pTα expression and lymphomagenesis,
two lines of Notch3-IC transgenic mice were crossed to pTα ko mice, and
animals selected at the F2 generation that lacked both alleles of pTα. Unlike
Notch3-IC/pTα-/+ mice, the follow-up of Notch3-ICpTα-/- mice until the age of
50 weeks showed neither splenomegaly or other histological or phenotypic
abnormalities of lymphoid organs nor early mortality in most of the mice, all of
which are properties of Notch3-IC/pTα-/+ mice.74 Indeed, only half of the
Notch3-IC/pTα-/- mice that died spontaneously after the age of 20 weeks
displayed tumor development at autopsy. Therefore, Notch3-IC/pTα-/- mice
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develop tumors, albeit with a reduced kinetics, only in about 10% of cases. In
contrast, the presence of a single copy of the pTα  gene allows tumor
development in Notch3-IC pTα-/+. Indeed, 95% of Notch3-IC pTα-/+ mice had
died by 40 weeks and all of them displayed tumor development at autopsy,
although tumor appearance and subsequent mortality were delayed with respect
to Notch3-IC pTα+/+ mice. These data establish that the causal role of activated
Notch3 in T cell lymphomagenesis in mice depends on pTα expression.
To study whether the absence of Notch3-induced tumors in Notch3-IC/pTα-/-
mice was due to a block of T cell development, as usually observed in pTα-/-
mice,128 we analyzed thymocyte maturation and peripheral T cell development
in Notch3-IC/ pTα-/- mice versus pTα-/- animals. Clearly, the lack of tumors in
Notch3-IC/pTα-/- mice cannot be attributed to impaired T cell development
and/or a reduction in peripheral T cells. Instead, T cell development through the
β-selection stage (that facilitates subsequent generation of CD4+CD8+
thymocytes) is rescued by Notch3 activation. We observed that the distribution
of thymocyte subsets and, to same extent, the cell yield and the surface
expression of TCR chain are rescued in Notch3-IC/pTα-/- mice. Moreover, an
increased number of T lymphocytes expressing the TCR chain on their surface
was observed in the spleen and lymphnodes of Notch3-IC/ pTα-/- mice compared
with pTα-/-. These observations suggest that activated Notch3, although able to
push immature T cells through preTCR-dependent development steps in the
absence of pTα , strictly requires pTα  expression for sustaining its
lymphomagenic potential.
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THE ROLE OF THE IKAROS GENE IN
L Y M P H O C Y T E  D E V E L O P M E N T  A N D
HOMEOSTASIS
PROPERTIES OF THE IKAROS GENE
In the search for transcription factors that control differentiation of the T cell
lineage, the Ikaros gene was isolated,129 which encodes a family of hemopoietic-
specific zinc finger proteins, described as a central regulator of lymphocyte
differentiation. During fetal development, it is required at the earliest stage of T
cell and B cell specification.
Ikaros is abundantly expressed in the day-8 yolk sac, the first site of extra-
embryonic hemopoiesis. Subsequently, its mRNA is detected in the day-9.5 fetal
liver primordium, a subsequent site of hemopoiesis in the embryo proper.129 At
these sites, Ikaros is expressed in hemopoietic progenitors and in erythroid and
myeloid precursors long before the appearance of fetal lymphocytes. Ikaros is
expressed in the fetal thymus from the beginning of its colonization by
hemopoietic progenitors that generate the fetal T lineages. High levels of Ikaros
mRNA are detected in maturing thymocytes in the fetal as well as in the adult
organ. It is also expressed in mature T and B lymphocytes and natural killer
cells. Within hemopoietic progenitors, Ikaros is expressed in the Sca-1+/c-kit+
population that is highly enriched for the pluripotent HSC.130It is equally
expressed in multipotent progenitors with a strong erythro-myeloid (Sca-1-/c-
kit+) and lymphoid (Sca-1+/ckit+/Sca-2+) potential. Although it is also expressed
in erythroid and myeloid precursors, it is turned off in most of their terminally
differentiated products.129 The highly restricted and complex pattern of Ikaros
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expression in embryonic, fetal, and adult hemopoietic sites qualifies this gene as
a potential regulator of cell fate in the fetal and adult hemopoietic systems.
Alternative splicing of Ikaros pre-mRNA results in a family of zinc finger
proteins.131-132 The zinc finger modules comply with the Kruppel C2-H2
consensus motif and are spatially arranged in two distinct domains. All of the
Ikaros proteins share a common C-terminal domain with two zinc fingers,
whereas their N-terminal domains contain different combinations of one to four
finger motifs. Three N-terminal zinc fingers are required for sequence-specific,
high-affinity DNA interactions on a single binding site.131 Therefore, of all the
Ikaros isoforms, only three (Ik-1, Ik-2, and Ik-3) bind to sequences that share a
four base pair core motif, GGGA.131 In contrast, one of the Ikaros proteins, Ik-4,
with two N-terminal zinc fingers, binds to tandem recognition sites that share
this sequence. In spite of the common core consensus, the overall DNA
sequence specificity and the affinity of binding varies between these isoforms.
At the other end of the spectrum, Ikaros proteins with one or no N-terminal zinc
fingers (Ik-5, Ik-6, Ik-7 and Ik-8) cannot engage in high-affinity DNA
interactions.131 The C-terminal zinc finger domain shared by all of the Ikaros
isoforms is utilized to engage these Ikaros isoforms in stoichiometric homo- and
heterodimeric complexes.133 These protein interactions are pivotal for Ikaros
activity. In fact, formation of homo- and heterodimers between isoforms with an
N-terminal domain capable of binding DNA (i.e. Ik-1, Ik-2, and Ik-3) increases
dramatically their affinity for DNA and activity in transcription.133 However,
heterodimers between DNA-binding- and non DNA- binding isoforms cannot
bind DNA and are transcriptionally inert. As a result, Ikaros isoforms lacking a
functional DNA-binding domain can interfere with the activity of DNA-binding
isoforms through a dominant negative mechanism. Ik-1 and Ik-2 are the
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predominant isoforms while Ik-3, Ik-4, Ik-5 and Ik-6 are present at significantly
lower levels in all hemopoietic cell populations studied.
MECHANISMS OF REGULATION OF GENE EXPRESSION
BY IKAROS
Commitment of hemopoietic progenitors toward lymphoid lineages is dependent
on the controlled activation or repression of gene expression. Chromatin
accessibility plays an important role in the transcriptional regulation of gene.
Transactivation studies have shown activating and repressing activity in
transient expression assays of promoters linked to Ikaros binding sites.134 The
large complexes that Ikaros proteins form with silent centromeric
heterochromatin in the nucleus colocalize with several genes that become
silenced during lymphocyte differentiation.135-137 Although this mechanism
explains how Ikaros might affect gene expression, the observation that some
genes can be silenced without being relocated to heterochromatin suggests that
control of gene repression is a more complex mechanism. Early biochemical
studies with Ikaros protein showed that it can interact with itself.133 This
property underlies the pronounced accumulation of wild-type Ikaros protein in
heterochromatin-associated structures and the inability of mutants in this
interaction domain to do so.137
In lymphocytes, most Ikaros is present in a 2-MDa complex that contains 10–12
Ikaros molecules as well as several other proteins.138 Characterization of the
main Ikaros-containing complex in T cells revealed the presence of Mi-2b, an
ATP-dependent chromatin remodeller (also known as Chd4), as well as the
HDACs HDAC1 and HDAC2. These three proteins are components of the
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nucleosome remodelling and deacetylation (NURD) complex that is active in
both chromatin remodelling and histone deacetylation. The previously
characterized NURD complex in epithelial cells also contains the MTA2
(metastasis-associated protein 2; also known as MTA1L1), MBD3 (methylCpG-
binding domain protein 3) and Rbp48/46 (RNA-binding proteins 48/46)
proteins.139-141 With the exception of MBD3, most of these factors are also
present in the Ikaros complex isolated from lymphocytes. Like its counterpart in
epithelial cells, the Ikaros–NURD complex has potent chromatin remodelling
activity in vitro and can deacetylate histones.142 Although most Ikaros in mature
lymphocytes exists in a NURD complex, a small amount is associated with the
SWI–SNF remodelling complex and with two other corepressors (the Sin3 and
CtBP proteins).142-145 The recent finding that the SWI–SNF complex also
contains the co-repressors Sin3, HDAC1 and HDAC2 provides a possible link
between the minority of Ikaros protein that associates with the SWI–SNF and
Sin3–HDAC components. Taken together, these biochemical studies show that
Ikaros is stably associated with enzymatic machines, remodellers and HDACs,
which could function during haematopoiesis by providing chromatin fluidity and
establishing chromatin codes. There are other possible mechanisms by which
Ikaros could affect gene expression. An important observation is that binding
sites for Ikaros have been found in the promoter of several lymphoid-specific
genes, suggesting that it could act as a classical transcription factor. In fact, it
has been identified a core consensus motif (C/TGGGA/T), recognized by Ikaros
transcription factor in the regulatory domains of the T cell receptor, i.e, TCR-α,
-β, and -δ genes and the CD3δ, -ε and -γ genes. Binding sites for Ikaros proteins
were also found in the promoters of CD4 and CD2, in the early pre-B cell
differentiation antigen mb-1, in the IL-2Rα, in the PRDII element of the beta
interferon gene, in the anti-apoptotic protein Bcl-2, in the enhancer of the H-2kb
30
gene and in the E-Ad promoter.146-154 Taken together, these results suggest that,
at least, one of the functions of Ikaros proteins is to act as repressor of
transcription by direct binding to promoters of target genes. Therefore, the
differential expression of the Ikaros isoforms during T-cell ontogeny, their
overlapping binding specificities and the different transcriptional activity and
nuclear localization, suggest a differential participation in distinct regulatory
pathways during lymphocyte development. Synergistic interactions and/or
competition between members of the Ikaros family proteins and other
transcription factors may explain the complex changes in gene expression
observed during lymphocyte differentiation and activation.
IKAROS FUNCTION IN VIVO: ROLE IN HEMATOPOIESIS,
T LYMPHOCYTE DEVELOPMENT, THYMOCYTE
SELECTION AND HOMEOSTASIS
The role of the Ikaros gene in development of the hemo-lymphoid system was
addressed first by the study of phenotype of mice deleted in the DNA binding
domain of the Ikaros gene, that results in a dominant negative
mutation.133Proteins generated by the Ikaros locus in which the DNA binding
domain is deleted cannot bind DNA. However, these mutant isoforms have an
intact C-terminal zinc finger dimerization domain and engage readily in protein
interactions. In lymphocytes heterozygous for this mutation, mutant Ikaros
proteins sequester the DNA binding isoforms made by the intact wild-type
allele, into transcriptionally inactive heterodimers.133 In addition, dominant
negative Ikaros mutant isoforms may interfere with the activity of other factors
that share similar dimerization domains and work in concert with Ikaros during
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development.155 The phenotype of mice homozygous for the Ikaros DNA
binding deletion (DN–/–) supports this hypothesis.156 In fact, Ikaros DN–/– mice
display an early and complete block in the development of all lymphoid
lineages, including T cells, during both fetal and adult hemopoiesis. In addition,
severe effects in the development of other hemopoietic lineages are manifested.
A five-to-tenfold decrease in erythroid and myeloid populations is observed in
the bone marrow, which is, however, compensated for by a dramatic increase in
extramedullary hemopoiesis in the spleen of these animals. Moreover, a severe
block in granulocyte differentiation is seen in these mice. Myeloid cells with a
granulocytic phenotype (Mac-1+/Gr-1lo/+) are absent. These more severe
hemopoietic defects may, in part, reflect the complete absence of T lymphocytes
that can provide necessary factors for granulocyte differentiation. They may also
relate a requirement in multipotent progenitors for Ikaros that is essential for
their expansion and differentiation along different arms of the myeloid pathway.
Low levels of expression of cytokine receptors as well as cytokines produced by
these progenitors and their progeny may interfere with their in vivo
differentiation, an effect that may be overcome in vitro when hemopoietic
growth factors are present in excess. Moreover, in absence of Ikaros activity a
30–40-fold reduction in HSC activity in the fetus and in the adult was
observed.157 Gene-expression studies in stem-cell and progenitor populations
sorted from Ikaros-null mice revealed, in fact, the deregulation of two tyrosine
kinase receptors that control the size of the HSC/progenitor pool.157 Expression
of the tyrosine kinase receptor fetal liver kinase 2 (Flk-2) was absent and c-kit
levels were reduced five to ten-fold. Analysis of Ikaros mutant mice phenotype
showed that Ikaros is not only required at the earliest stage of T cell
specification, but also later in thymocyte selection and homeostasis. T cell
development begins in the thymus of the Ikaros-null mice a few days after they
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are born.158 Thymocytes that are polyclonal in their TCR repertoire and that
have a propensity to differentiate into the CD4 lineage are detected from 3 to 5
days after birth. TCR stimulation of CD4+ and CD8+ thymocytes in Ikaros-null
mice results in excessive proliferation, compared to wild type.158 As early as five
days after the appearance of T cells in the thymus of these mutant mice,
thymocytes with the same TCR specificity are found expanding in all three of
the CD4+/CD8+, CD4+, and CD8+ compartments. In older animals, monoclonal
T cell populations of similar phenotypes take over and replace the polyclonal
thymocyte repertoire. These T cells are of a malignant nature and are also found
in increased numbers in the periphery at later times. Deregulated T cell
homeostasis is also manifested in mice heterozygous for the dominant negative
DNA binding mutation in Ikaros (DN+/–).159 In contrast to the Ikaros-null
homozygotes, DN+/– mice are born with “apparently normal” lymphoid
compartments. However, in the DN+/– mice, as in the Ikaros-null, thymocytes
display augmented proliferation when triggerred via the TCR complex. Changes
in the composition of the thymocyte compartment are detected in the aging
heterozygotes, with kinetics that are relatively delayed compared to those
observed in the thymus of the Ikaros-null mice. Expansion in the intermediate
double positive (CD4+/CD8int/TCRint and CD4int/CD8+/TCRint) and in single
positive (CD4+/TCRhi and CD8+/TCRhi) thymocytes is detected between the
second and third month. Ikaros DN+/– mice develop a lymphoproliferative
disorder between the third and sixth month of their lives.159 The hallmark of the
disease is the dramatic accumulation of clonal lymphoblastic T cells in all
peripheral lymphatic centers, accompanied by invasion of other tissues. Within a
given animal, a percentage of these lymphoblastic T cells express the CD25
activation marker. This percentage varies between populations and correlates
with the stage of disease. At late stages, defined by lymphoid organs that are
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greatly enlarged in size and dominated by clonal lymphoblastic T cells, the great
majority of these cells express the CD25 activation marker. The surface
phenotype of accumulating thymocytes at the onset of the lymphoproliferative
syndrome suggests that TCR engagement, followed by a series of deregulated
downstream signaling events, may trigger the initial expansion of double
positive thymocytes during selection. After their initial expansion, these Ikaros-
mutant thymocytes can further differentiate to a single positive state. Persistence
of TCR-engaging antigenic stimuli, such as superantigens from endogenous
retroviruses expressed on epithelial cells of the thymus and peripheral lymphatic
centers, in combination with deregulated TCR signaling, may underlie the
dramatic accumulation of peripheral lymphoblastic T cells with a mature and
activated phenotype (CD25+). The highly malignant nature of Ikaros DN+/–
lymphoblasts was established in adoptive transfer experiments. Tumors with the
same cell surface phenotype and genetic makeup as the input cells are detected
shortly after their transfer to nude mice. These cells invade not only peripheral
lymphatic centers but also all of the host organs. The highly aggressive and
malignant phenotype of these cells suggests that they have evaded growth factor
requirements and proliferative signals usually supplied by the thymic, splenic, or
lymph node microenvironments. Genetic analysis of the malignant T cells in the
Ikaros DN+/– mice revealed loss of Ikaros heterozygosity. However, these
malignant cells contained a normal number of chromosomes, indicating that the
loss of the wild-type allele was due either to aberrant mitotic segregation of the
two mutant alleles or to a gene conversion event. The majority of such cases
lead to lethality or confer no selective advantage to the mutated cell. However,
the segregation of chromatids with a mutation in the Ikaros gene may present
cells with a growth advantage over other cells and thus establish the first stage in
neoplasia. Such events have been described in the tumor progression of cells
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heterozygous for mutations in tumor suppressor genes such as p53 and
retinoblastoma.160-161
The TCR-driven hyperproliferative phenotype of thymocytes in mice
homozygous for a null and heterozygous for a dominant negative Ikaros
mutation strongly suggests that this gene is required for the negative regulation
of TCR signaling and proliferation of immature thymocytes. The role of Ikaros
in T cell differentiation was further delineated breeding Ikaros DN+/– with RAG-
1–/– mice. Thymocytes from RAG1–/– mice can’t rearrange TCR genes and
consequently do not express a preTCR complex, so they arrest their
development at an early precursor stage (DN CD44–CD25–). Pre-TCR signaling
is required for progression to the next stage of differentiation where both CD4
and CD8 coreceptors are expressed (CD4+CD8+). It is also required for the
proliferative expansion of thymocytes during ths transition. However, in the
absence of Ikaros activity, thymocyte precursors can transit from the double
negative to the double and CD4 single positive stages without the signaling
events provided by preTCR and TCR engagement. However, this differentiation
event occurs without the normally occurring proliferative expansion, resulting in
a highly hypocellular thymus. Thus, lack of Ikaros activity in thymocyte
precursors uncouples the process of differentiation from that of proliferation,
allowing the one to occur in the absence of the other. Interestingly, the
preferential development of CD4 lineage cells observed in Ikaros null–/– x
RAG–/– thymi correlates with the phenotype previously reported for Ikaros
null–/– thymi without the RAG mutation. Therefore, Ikaros plays a central role in
establishing thresholds for differentiation that give rise first to double positive,
and subsequently to CD4 single positive thymocytes.
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IKAROS AS AN ESSENTIAL TUMOR SUPPRESSOR GENE
FOR THE T LINEAGE
A stepwise decrease in Ikaros activity in developing thymocytes leads to their
inappropriate selection, expansion, and finally to their transition to a neoplastic
state. Differences not only in the kinetics of appearance but also in the
phenotype and properties of lymphoblastic T cells generated in Ikaros-mutant
mice can be related to the level of functional Ikaros in these cells. In the
presence of one wild-type and one dominant negative mutant Ikaros allele,
clonal expansions become apparent after one to two months of age and are
concomitant with the loss of the wild-type locus.
Ikaros DN+/– develop leukemias and lymphomas with 100% penetrance within 3
months of life.159 Interestingly, when a cohort of Ikaros DN+/– x RAG-1–/– mice
was followed for 11 months, no lymphomagenesis was observed, whereas when
mice transgenic for TCR were bred with Ikaros DN+/– x RAG–/– mice, thereby
restoring T cell differentiation, the transformation phenotype could be
restored.160 Therefore, expression of a functional preTCR or TCR complex at
subsequent stages of differentiation is necessary for Ikaros deficiency to have a
destabilizing effect on T cell homeostasis and trigger proliferative events that
led to malignancy. These studies implicate Ikaros as a critical regulator of the
preTCR mediated checkpoint in T cell differentiation known as β-selection.
Intriguing is the observation that, similarly to what happens in Notch3-IC
transgenic mice, the development of leukemia arising in Ikaros mutant mice is
depending on either pre-TCR or TCR signaling whereas DN thymocytes can
differentiate to the DP stage without expression of pre-TCR.160Therefore, the
Ikaros gene family is essential for the development of T lymphocytes and
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functions as tumor suppressor in T and B cells.156,161,159 The fact that Ikaros
functioned as a tumor suppressor gene in mice suggested that Ikaros expression
alteration could be involved in human hematological malignancies. Actually, it
has been shown that reduction in Ikaros activity correlates with development of
blast crisis in patients with chronic myelogeneous leukemia.162-163 Bone marrow
from those patients show either a reduced expression of Ikaros at the RNA level
or an overexpression of dominant negative Ikaros isoforms. Therefore, reduction
of Ikaros activity may be an important step in the development of blast crisis in
chronic myelogenous leukemia.162 Mutations that cause overexpression of
dominant negative Ikaros isoform are also involved in human B and T cell acute
lymphoblastic leukemias.164-165 Similarly to the observation made in Ikaros DN
–/+ mice, aberrant expression of a dominant negative Ikaros isoform has been
reported in T acute lymphoblastic leukemia in infants,166 and moreover, an
abnormal subcellular compartimentalization of Ikaros, with exclusive
cytoplasmic localization, was observed. These results indicate that post-
trancriptional regulation of RNA alternative splicing is defective in leukemic
cells from infants with ALL.164-166
Overexpression of dominant negative Ikaros isoforms might be the consequence
of abnormal splicing accompanied by a 10 amino acids deletion adjacent to exon
7 or by a 60 base pair insertion following exon 2.162
 In mice model, diminution of Ikaros expression causes hyperstimulation
through antigen receptor leading to polyclonal lymphoid hyperplasia prior to
tumoral transformation. Although Ikaros DN+/– mice develop T cell
leukemia/lymphoma in 100% cases before the age of 6 months, transformation
might be the direct consequence of the hyperproliferation state.  In fact, Ikaros
seems to be directly involved in cell cycle regulation throughout the regulation
of expression of p27 (one of the few genes that is upregulated by Ikaros), and
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cyclin D1.168-169 An interesting observation was made by Beverly and
Capobianco that, by using proviral insertion mutagenesis with moloney murine
leukemia virus (MLV) demonstrated a direct link between Ikaros deficiency and
Notch activation in T cell lymphomas. In fact, they observed that Ikaros locus is
a common target of proviral integration in 40% of tumors arising in Notch1-IC
transgenic mice. Such proviral insertion-dependent mutations lead to the
production of dominant negative Ikaros isoforms that finally may sinergize with
activated Notch1 during tumorigenesis, being able to inhibit the repression
sustained by DNA-binding isoforms of Ikaros on Notch-dependent genes. Thus,
Lck-Notch1-IC transgenic mice infected intraperitoneally with MLV increased
the penetrance of leukemia from 20% to 100%.
Moreover, these authors observed that Ikaros and the Notch effector protein
CSL/RBP-Jk were capable to recognize the same DNA-binding sequence in
vitro, the core motif TGGGAA. Therefore, they suggested a model in which
Ikaros may antagonize Notch-IC/CSL –induced transcriptional activation by
competing with the similar consensus DNA-binding motif.169 More recently, S.
Chan’s group demonstrated that re-introduction of a functional Ikaros in Ikaros
mutant mice downregulates Notch target gene expression in tumor cells and
inhibits the Notch-induced CSL/RBP-Jκ transcription on the target sequence in
HES-1 promoter.170 Altogether, these observations clearly suggested a
connection between Ikaros deficiency and Notch activation in T cell
leukemogenesis, without indicating the direct targets and/or mediators of such a
connection.
38
THE RNA BINDING PROTEIN HUD
Transcription factors have traditionally been viewed as the main determinants of
gene expression. Yet, in recent years it has become apparent that RNA-binding
proteins also play a critical role in determining the levels of expression of a large
number of genes. Once mRNAs are transcribed, RNA-binding proteins can
control all subsequent steps in their function, from alternative splicing and
translation to mRNA transport and stability. From this point of view, a good
example is represented by the nervous system, in which a large number of genes
are regulated post-transcriptionally via the interaction of their mRNAs with
specific RNA-binding proteins. This type of regulation is particularly important
in the control of the temporal and spatial pattern of gene expression during
neural development.
There are a number of well-characterized RNA binding proteins that have been
shown to assume specific roles in normal neuronal development and function,
such as CPEB, ZBP and FMRP.171-173
Over the last 15 years, there has therefore been growing interest in the function
and regulation of the Hu family of RBP, which is directly involved in
development of paraneoplastic encephalomyelitis and sensory neuronopathy
sydromes.174-176
The antibody produced in the above disorder was termed anti-Hu based on the
name of the patient in which the antibody was discovered.175,177 The Hu antibody
was used to identify HuD and other Hu protein.175 Upon cloning and sequencing
of these proteins,175,178 it was found that they are the human homologues of
Drosophila ELAV, an RNA-binding protein whose deletion results in an
embryonic lethal abnormal vision phenotype in flies.175 Thus, to refer to this
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family we will use the name of ELAV/Hu herein. There are four mammalian
ELAV/Hu proteins, HuA also known as HuR, HuB also known as Hel-N1, HuC,
and HuD. These proteins are encoded by separate genes and are present in the
cell in multiple splice variants. In mammals, birds, and Xenopus, three proteins
of this family (HuB, HuC, and HuD) are neuronal-specific, while the fourth
member, HuA, is expressed in other tissues. Hu proteins are thought to be one of
the earliest markers of neuronal differentiation.179-180All four of the Elav/Hu
family members contain three RNA recognition motifs (RRMs), a highly
conserved 80 amino acid region, that was first recognized in splicing factors and
poly(A)-binding protein.181
RRM is a conserved structure of two consensus ribonucleoprotein (RNP) motifs
separated by 25–35 amino acids that interact directly with the RNA. The RNP
motifs, octameric RNP-1 and hexameric RNP-2, each contain three conserved
aromatic residues that are implicated in RNA interactions in a number of
different RBP including proteins that bind pre-mRNA, mRNA, pre-rRNA as
well as small nuclear and heteronuclear RNAs.
HuD, in particular, is encoded by a relatively large gene (146 Kb) located on
chromosome 1 in humans (1p34) and chromosome 4 in mice (49.5 cM). Some
of the exons are separated by large intronic regions. The localization of the HuD
gene in the mouse genome was based on syntenic regions between human and
mouse, suggesting that the flanking genes are conserved between species.182
The gene consists of three putative non-coding exon 1 variants, termed 1a, 1b
and 1c, and several common coding exons (2, 3, 4, 5 and 8).183-184 The first and
second RRM are encoded by exons 2 and 3, and exons 4 and 5, respectively,
while the third RRM is encoded by exon 8. The HuD gene is also subject to
alternative splicing of exons 6 and 7 which affects the length of the hinge region
linking the second and third RRM. This results in the three different transcripts
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and molecular forms, termed HuDpro, HuD and HuDmex183 of which HuDpro
and HuD are the major variants.182-185 The resulting proteins have molecular
masses ranging between 37 and 43 kDa and are characterized by the three
RRMs and unique nuclear export signals located within the hinge region.186
HuD has long been known as one of the earliest markers of neural
differentiation.187 Several in vivo and in vitro experiments indicate an important
role of neuron-specific HuD proteins in multiple aspects of neuronal function
including the commitment and differentiation of neuronal precursors as well as
synaptic remodeling in mature neurons.
HuD proteins recognize and bind specifically to well-described AU-rich
elements (ARE) found within the 30 UTR of approximately 1 in 20 human
genes188-189 and directly implicated in RNA turnover.188-191 The AREs are
separated into three classes based on their sequence and structure. Class I AREs
consist of one to three dispersed AUUUA motifs separated by U-rich regions
while class II AREs consist of multiple clusters of AUUUA motifs. Class III
AREs, although less-well defined, consist mainly of U-rich sequences and do
not contain the AUUUA pentamer.192
Unlike many other ARE-binding proteins that principally act to destabilize
transcripts, such as AUF1 family members, Hu proteins act to stabilize ARE-
containing transcripts thereby significantly prolonging heir half- life.193-195 In
vitro binding studies perfor med with HuD have demonstrated that the RNA is
bound primarily by the first RRM while the second RRM, which also binds the
RNA, functions mostly to stabilize the RNA–protein complex.196 The third
RRM, in addition to participating in maintaining RNA–protein complex
stability, binds to poly(A) tails.197-200
As the variety of cis-acting elements recognized by the RRM have increased, so
have the number of transcripts that interact with HuD. Accordingly, HuD has
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been shown to bind and stabilize several developmentally regulated transcripts
including c-fos, c-myc, N-myc, p21waf1, neuroserpin and MARCKS.201-206
Interestingly, and in agreement with its role in neuronal differentiation, many of
the transcripts bound by HuD play a key role in the formation of neuronal
processes such as GAP-43 and tau.
Additionally, the role of HuD in multiple aspects of a neuron’s life from early
differentiation to changes in mature neurons during learning paradigms and in
response to injury and regeneration.207
More recently, HuD has also been described in the CD34– subset of bone
marrow cells, suggesting a role for this RNA-binding protein also in the
hematopoietic system.208Finally, after evidence of nuclear-cytoplasmic
shuttling209-210 and the predominant nuclear localization,211HuD proteins have
been reported to have a nuclear function. In Drosophila, the HuD protein
homologue, the embryonic lethal abnormal visual (ELAV) protein, has been
shown to have a very important function in the nucleus, where regulates
alternative pre-mRNA processing in neurons.212-214 Recently, we and others have
demonstrated that HuD proteins may regulate alternative splicing in thymocytes
and mammalian neurons, identifying two target sequence of HuD proteins,
Ikaros and the human calcitonin/calcitonin gene-related peptide (CGRP) pre-
mRNA (Zhu).168,215 The role of Hud in regulating Ikaros splicing will be treated
in more details in the section reporting my activity during my phd.
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EXPERIMENTAL THESIS
INTRODUCTION
The process of T-cell leukemogenesis is regulated by some of the same
mechanisms that control T-cell differentiation, and the final outcome depends on
fine balancing. Both processes are known to be affected by aberrantly activated
Notch signaling and by the loss of function of the transcription factor, Ikaros
(IK), depending on the presence of a functional pre-T-cell receptor (pre-
TCR).74,159-160Our previous studies in transgenic mice expressing the
intracellular domain (IC) of the Notch3 receptor (N3-IC) have shown that
constitutive Notch3 signaling leads to the persistent overexpression in
thymocytes of the pTα chain, an essential component of the pre-TCR. This
overexpression is a hallmark of the T-cell leukemia/lymphoma that ultimately
develops in these animals.101 Interestingly, by generating double mutant mice
transgenic for Notch3-IC and lacking pTa (N3-IC/pTα-/- mice), we observed
that an intact pre-TCR is required for T-cell leukemogenesis,74 although it is not
required for Notch3-driven T-cell differentiation.
Indeed, whereas pTα knockout arrests T-cell development, transgenic N3-IC
overcomes this block, driving immature CD4CD8 double-negative (DN)
thymocytes to progress toward a more differentiated phenotype (e.g. acquisition
of CD4, CD8 and TCRβ expression) despite the absence of a functional pre-
TCR.74
An intriguingly similar picture emerges when we analyze the effects of the loss
of IK activity. Dominant mutation that eliminates the DNA-binding activity of
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this transcription repressor leads to rapid development of murine leukemia and
lymphoma, which is strictly dependent on either pre-TCR or TCR signaling,159
and yet IK-deficient DN thymocytes can differentiate to the CD4+CD8+
double–positive (DP) and CD4+ single-positive stages in the absence of a pre-
TCR complex.160 Therefore, like constitutive activation of Notch3, loss of IK
function is characterized by pre-TCR-independent thymocyte differentiation
from the DN to the DP stage and pre-TCR-dependent expansion of immature
thymocyte populations.74,160 The roles of Notch and IK in human
leukemogenesis are supported by several reports. Notch3 overexpression has
been observed in virtually 100% of human T-cell acute lymphoblastic
leukemia/lymphomas (ALL), including tumors from all major molecular and
immunophenotypic subtypes,74 and activating mutations of  Notch1 have been
found in over 50% of these tumors.106 A high percentage of infant B- and T-
ALLs also display an increased expression of short non-DNA-binding IK
isoforms.165-166 Alternatively spliced transcripts of the ikaros gene encode at
least nine protein isoforms (IK-1–9) with different DNA-binding
capabilities.131,169,216
Isoforms IK-1–3 are characterized by at least three N-terminal zinc-finger motifs
that allow efficient DNA binding. Shorter isoforms, lacking one or more of these
DNA-binding motifs, form heterodimers with full-length isoforms and exert
dominant-negative effects that can decrease or even suppress normal IK activity.
It has recently been suggested that increased expression of dominant-negative
IK isoforms (IK-dn) and constitutively activated Notch play cooperative roles in
leukemogenesis, involving effects that may converge in the transcriptional
regulation of one or more key genes.169 However, the identity of these putative
common targets is still obscure, and thus far there has been no demonstration of
a direct link between aberrant Notch signaling and alterated IK isoform
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expression. In the present paper, we show that Notch3 activation upregulates the
expression in thymocytes of the RNA-binding protein HuD. This effect results
in the increased expression of IK-dn isoforms, which diminishes the DNA-
binding activity of IK and, consequently, its ability to inhibit Notch3-induced
increase of pTα  expression. These events could be expected to lead to a
persistent activation of pre-TCR signaling, which is responsible for the
triggering of a number of oncogenic pathways.
Notch3 and the hematopoietic nuclear factor IK cooperate in the regulation of T-
cell development and lymphomagenesis. The molecular model portrayed by our
findings (Figure 8) is characterized by crosstalk among Notch3, IK and the
pTα/pre-TCR signaling activity that is mediated in part by the RNA-binding
protein HuD. Its pre-TCR-dependent upregulation, specifically induced by
Notch3, diminishes the IK–induced repression of transcriptional activation of
pTa, an effect that appears to be related to regulation of the differential splicing
and/or the stability of IK mRNAs. This is the first evidence that the RNA-
binding protein HuD plays a role in the complex scenarios of T-cell
differentiation and tumorigenesis.
MATERIALS AND METHODS
MICE
The generation and typing of N3-Ic tg,101 pTα-/-217 and N3-IC/pTα/ double
mutant mice74 have been described elsewhere.
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FLOW CITOMETRY ANALYSIS
Freshly isolated cells from thymi and lymph nodes were prepared and stained as
previously described101 and analyzed on a FACScan (BD Biosciences, Mountain
View, CA) using CellQuest software (BD Biosciences). Forward and side scatter
gatings were used to exclude dead cells from the analysis. Cells were stained
with anti-CD4-FITC and anti-CD8-PE antibodies (BD PharMingen). PE- and
FITC-conjugated rat IgG (BD PharMingen) were used as a control for
immunofluorescence.
CELL SORTING
Thymocyte suspensions from wt, Notch3-IC tg, Notch3-IC/pTα/ and pTα/ mice
were prepared and stained with anti-CD4-FITC and anti-CD8-PE antibodies as
described above. CD4–CD8– DN and
CD4+CD8+ DP subsets were then separated (purity level X95%) with the
FACSAria cell sorter (BD Biosciences).
RT–PCR ANALYSIS
Total RNA was extracted from unfractioned T lymphocytes (both from thymi
and lymph nodes), from CD4+CD8+ and CD4–CD8– sorted thymocytes, from
untransfected and transfected M31, pre-T-cell line 2017218 and human Molt-3
cell line, and from different samples of human ALLs and relative controls, using
Trizol (Gibco) following the manufacturer’s protocol. A 1 mg portion of RNA
was processed for RT–PCR as previously described.72 PCR was performed at
the appropriate annealing temperature with the following primers: IK 5’-
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CTCCAGATGAAGGGGATGAG-3’ and 5’-CAGCAGCAGCAAGTTATCCA-
3’, IKexon7 5’- TGGTTATCACAGCCAGGACA-3’ and 5’-
A A A T C A A A C G C C A A A C A A C C - 3 ’ ;  H u D  5 ’ -
AGAAGGGAATGTCAGCTTTT-3’ and 5’-TGAATTCCTCTTGGGTCATA-
3’;219b-actin 5’-GTGG GCCGCTCTAGGCACCAAT-3’ and 5’-
C T C T T T G A T G T C A C G C A C G A T T T C - 3 ’ .  H u m a n  I K :  5 ’ -
C C C C C T G T A A G C G A T A C T C C A G A T - 3 ’  a n d  5 ’ -
GGCTTGGTCCATCACGTGGGGA-3’; human HUD: 5’-GAGTCTCTT
CGGGAGCATTG-3’ and 5’ -CTTGTGGGCTTTGTTGGTTT-3’ ; mouse Hes-
1 :  5 ’ - A T G C C A G C T G A T A T A A T G G A G - 3 ’  a n d  5 ’ -
C A C G C T C G G G T C T G T G C T G A G - 3 ’ ;  m o u s e  D e l t e x :  5 ’ -
CACTGGCCCTGTCCACCCAGCCTTGGCAG-3’ and 5’-ATGCGAATT
CGGGAAGGCGGGCAACTCAG-3’; mouse Notch3: 5’-CCAGGGCTGC
AACACTGAGGAATG-3’ and 5’- TTGTGGCCAGCAGCTATGTCCTTG-3 ;
mouse pTalpha: 5’-GCGAT GCTTCTCCACGAGTGGGC-3’ and 5’-
GCGCTATGTCCAAATTCTGTGGG-30 ;  human b-actin: 5’-
CTACAATGAGCTGCGTGTGG-3’ and 5’- CGGTGAGGATCTTCATGAGG;
mouse Notch1 : 5’-GTGGATGCTGACT GCATGGATGTC-30 and 50 -
ATGCAAAGCCGACTTGCCTAGGTC-30 ; human Notch1: 5’-
CTACCTGTCA GACGTGGCCT-3’ and 5’-CGCAGA GGGTTGTATTGGTT-
3’ ; human Notch3: 5’-TTCTTAGATCTTGGGGGCCT-3’ and 5’-
G G A A G A A G G A G G T C C C A G A C - 3 ’  ;  h u m a n  p Tα : 5’-
CTGCAGCTGGGTCCTGCCTC-3’ and 5’-AGTCTCCGTGGCCGGGTGCA-
3’. To quantify transcript expression levels, PCR was carried out in the linear
exponential phase of amplification through 20–35 cycles. Sample loading was
monitored by a b-actin transcript that was subjected to the same treatment. IK
PCR products were analyzed by agarose gel electrophoresis followed by
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Southern blotting and hybridization with a probe specific to the amplified
sequences.
WESTERN BLOT ANALYSIS
Whole-cell extracts were prepared as described previously.169 In brief, 50 mg of
protein extraction from each sample was subjected to SDS/PAGE, transferred to
nitrocellulose membrane and probed with the following antibodies: anti-IK (SC-
9861, Santa Cruz Biotechnology Inc.) and anti-tubulin (SC-8035, Santa Cruz
Biotechnology Inc). Bound antibodies were detected with enhanced
chemiluminescence (ECL kit, Amersham).
CELL LINES
Transient transfection experiments were performed using the pre-T-cell line
2017218and M31 immature T-cell line.220
PLASMIDS
IKcDNAs were cloned from RT–PCR reactions from both wt and Notch3-IC
transgenic thymi as previously suggested.169The fragment containing the
putative pTα promoter region (pubMed sequence U27268) was amplified by
PCR from genomic DNA using the primers pTa-prom-FL 5’-
GCTTTGGATCTGGAGGATGA-3’ and 5’-CTCTGCTAGTCTGCCTCCCA-3’
and subcloned in topo TA-cloning (Invitrogen, Carlsbad, CA, USA). The pTa
promoter-luciferase fusion plasmids were constructed by cleaving with XhoI
and SacI the PCR products and inserted into the XhoI and SacI sites upstream of
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the luciferase cDNA of pGL3-basic vector (Promega, Madison, WI, USA). The
mutant constructs pTa-prom-FL CSL1MUT and pTa-prom-FL CSL2MUT and
CSL3MUT were prepared using QuikChangeTM site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) according to the instructions of the
manufacturer. MAM was cloned in pFLAG- CMV2 as previously
suggested.39,169 HuD was amplified by PCR by using the primers HuD 5’-
GGGTCCATCTTCTGATCACA-3’ and 5’-GGGTGAGAAATTCAGGATTT-
3’ and cloned in pcDNA3.1/V5-His-TOPO (Invitrogen, Carlsbad, CA, USA)
expression vector. All the correct clones were confirmed by sequencing. The
expression vectors for Notch3-IC101and RBP-Jk,221were previously described.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
IK-1 and CSL proteins were produced in transfected Cos cells using expression
vectors containing IK-1 or CSL cDNA. Nuclear extracts were prepared
(according to Dumortier et al, 2006)170 by resuspending 107 cells in 500 ml of
lysis buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl2; 10 mM KCl; and 0.5 mM
dithiothreitol (DTT)). After 10 min, cells were vortexed and nuclei were pelleted
and resuspended in 50 ml of the following buffer: 20 mM HEPES, pH 7.9; 25%
glycerol; 420 mM NaCl; 1.5 mM MgCl2; 0.2 mM EDTA; 0.5 mM DTT;
protease inhibitor cocktail. Lysates were kept on ice for 20 min and vortexed
thoroughly. After centrifugation, supernatants (nuclear extracts) were quantified
using the Bradford colorimetric assay. Three micrograms of nuclear extract was
used for each sample.
Samples were incubated for 25 min at room temperature with 2 mg of poly(dI-
dC), 1 mg of bovine serum albumin and 10 mM ZnCl2 in 19 ml of HGDE buffer
(20 mM HEPES, pH 7.9; 0.2 mM EDTA; 20% glycerol; 100 mM KCl; and 1
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mM DTT). End-labeled, double-stranded probe was then added to each reaction
mixture and the mixture was incubated for 20 min at room temperature.
Protein–DNA complexes were resolved on a 5% polyacrylamide gel, dried and
analyzed by autoradiography. The following probes were used: CSL: 5’-
AGGAACTAGGCTTGGGAAAGGCTTTGAGAAT-3’; CSLMUT1: 5’-
AGGAACTAGGCTTAGTACAGGCTTTGAGAAT-3’.
SiRNA SILENCING
Mouse and human Notch3, HuD and control and human Notch1 siRNA
(Dharmacon, Lafayette, CO, USA) were incubated in OPTI-MEM (Gibco,
Gaithersburg, MD, USA) for 10 min at room temperature with Hy-perfect
transfection reagent (Qiagen, Hilden, GE) at a final siRNA concentration of 5
nM. Complexes thus formed were added dropwise onto the cells (4x105 per well
in a 24-well plate in 0.5 ml of RPMI medium containing FBS and antibiotics)
and incubated for 72 h after transfection. To study Molt-3 cell survival/
proliferation after siRNA, 3x106 cells/well were plated in a six-well plate; 72 h
later, total cell recovery was evaluated.
COCULTURE EXPERIMENTS
OP9 stromal cells, kindly provided by Dr A Rolink, were mantained in
ISCOVE’S modified supplemented medium, supplemented with 20% fetal
bovine serum, 2% penicillin, 1% L-glutamine and 2% sodium pyruvate, and
plated 1 day before use to achieve a confluent monolayer of cells. Cocultures
were initiated with 4x106 2017 cells with or without 10 mM of g-secretase
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inhibitor I (alternate name Z-LLNLe-CHO; Calbiochem, San Diego, CA, USA)
and harvested after 48 h for RNA extraction.
CELL TRANSFECTIONS AND LUCIFERASE ASSAYS
Trasfection of the pre-T-cell line 2017 and M31 cell line was performed using
the lipofectamine 2000 kit (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Renilla luciferase reporter vector pTK-Renilla-Luc
(0.5 ng) was also incorporated into each transfection (Promega, Madison, WI,
USA) for normalization. The total amount of transfected DNA was kept constant
by adding empty vector. At 48 h post-transfection, the cells were lysed in a
reporter lysis buffer (Passive Lysis Buffer; Promega, Madison, WI, USA) at 120
ml/well. Firefly- and pRL-TK-derived Renilla luciferase activities were
measured in each sample with the Dual luciferase Assay System (Promega,
Madison, WI, USA) using a Model TD-20/30 luminometer (Turner Designs).
Light emission was measured for 10 s after injection. The specific luciferase
activity of different transfections was determined in triplicate samples and was
normalized on the Renilla luciferase activity. Data were expressed as means7s.d.
of at least three independent experiments. Transient transfection efficiency in
M31 and 2017, as assessed by expression of a GFP expression vector added in
trace amounts, was about 70 and 40%, respectively.
ChIP ASSAY
Protein complexes were crosslinked to DNA in living nuclei of freshly isolated
thymocytes to a final concentration of 1%. Crosslinking cells were processed, as
previously described107and divided into aliquots. In total, 5 mg of antibody (anti-
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RBP-Jk sc-28713X, anti-IK sc-13039, rabbit IgG sc-2027, Santa Cruz
Biotechnology Inc.) was added to each aliquot of chromatin and incubated on a
rotating platform for 12–16 h at 41C. Antibody–protein–DNA complexes were
isolated by immunoprecipitation with salmon sperm DNA/Protein A agarose
(#157, Upstate Biotechnology). Following extensive washing, bound DNA
fragments were eluted and analyzed by subsequent PCR using the following
primers specific for the pTa mouse promoter including the CSL-core1 site: 5’-
GCTTTGGATCTGGAGGATGA-3’ and 5’-GAACTCAGGTCCCACTCCCA-
3’.
RESULTS
Notch3-IC transgenic mice display increased expression of alternatively
spliced IK isoforms
To better define the relationships between IK and Notch3 in the processes of T-
cell differentiation and leukemogenesis, we first analyzed IK isoform expression
in premalignant thymocytes from young (2-week-old), wild-type (wt) and N3-
ICtg mice. We define the line between preleukemia and leukemia by the finding
of CD4+CD8+ DP cells in the spleen of transgenic mice. The two groups of cells
were similar in terms of thymocyte subset distributions (Figure 1A), but the N3-
ICtg cells displayed increased expression of IK-dn isoforms at both the RNA
and protein levels (Figure 1B, upper and lower panels, respectively). We then
investigated IK protein expression in adult N3-ICtg mice that had already
developed unequivocal signs of leukemia/lymphoma.101Thymocytes (Figure 2A,
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upper panels) and peripheral T-cells (i.e. lymph node cells) (Figure 2A, lower
panels) from these animals exhibited significantly increased expression of the
IK-dn isoforms (compared with wt littermates). The IK isoform profiles were
unrelated to the immunophenotype of the lymphoma cell, which can vary from
animal to animal.101In fact, similar profiles were observed in cells with different
immunophenotypes (e.g. N3-ICtg3 and N3-ICtg4 in Figure 2A and B), and those
with identical phenotypes sometimes had different IK expression profiles
(although the increase in IK-dn isoforms was a constant) (data not shown). It is
interesting to note that in each tumor-bearing mouse, thymus- and lymphnode-
derived lymphoma cells consistently displayed identical immunophenotype
(Figure 2A). Similar IK isoform profiles were also observed at protein levels
(Figure 2B).
Noteworthily, the IK-9 isoform, of intermediate size with respect to IK-1 and
IK-2/3, appears mainly represented in all the samples obtained from N3-ICtg
cells. This isoform, previously described by Beverly and Capobianco,169 includes
all the exons except exon 4, which encodes the critical DNA-binding zinc-
fingers, and thus behaves as dominant negative. We cloned and sequenced IK
isoforms from thymocytes of both Notch3-IC and wt mice, and Supplementary
Figure 1 schematically represents the bands more represented, including the
distribution of zinc-finger motifs and the size range of RNA.
The pTa/pre-TCR is required for Notch3-induced redistribution of IK
isoforms
Previous work has shown that the presence of the pre-TCR is necessary for
Notch3-induced leukemogenesis74and for that observed in mice with a dominant
DNA- binding mutation in the IK gene.159-160
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We hypothesized that increased expression of IK-dn isoforms is characteristic of
Notch3-dependent leukemia and may also contribute to its development. To
investigate this possibility, we compared the IK isoform expression profiles of
thymocytes from N3-ICtg mice, double mutant N3-ICtg/pTα/ mice, pTα/ mice
and wt controls. DN (CD4–CD8–) and DP (CD4+CD8+) thymocytes were sorted
and analyzed separately to minimize the effects of any strain-related differences
in thymocyte subset distributions. As shown in Figure 3A, the shift toward IK-
dn expression observed in N3-ICtg thymocytes was absent in both N3-
ICtg/pTα/ and pTα/ cells, which lack a functional pre-TCR complex.
Intriguingly, semiquantitative RT–PCR amplification of IK exon 7 (present in
all of the isoforms) revealed that total IK transcript levels in DN and DP
thymocytes from N3-ICtg/pTα double mutant mice were significantly lower
than those observed in wt, N3-ICtg and pTa/ cells (Figure 3A, middle panels).
These findings were confirmed at the protein expression level by Western blot
analysis of total cell extracts from unfractionated thymocytes (Figure 3B).
Notch3 modulates expression patterns of IK mRNAs and proteins in vitro
Our next step was to determine whether Notch3 signaling directly affects IK
isoform expression. The in vivo findings presented above indicated that such an
effect is probably dependent on the presence of an intact pre-TCR. Based on
CD25 and CD44 expression, DN thymocytes can be divided into four subsets,
DN1–4, and functional pre-TCR expression is first observed at the DN3
(CD25+CD44–) stage. Therefore, we compared Notch3-induced IK splice variant
profiles in DN1 and DN3 cells represented respectively by the M31220and
2017218cell lines (Supplementary Figure 2). The two cell lines (both of which
constitutively express full-length DNA-binding IK isoforms) were transiently
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transfected with increasing amounts of N3-IC, and IK isoform profiles were
investigated 48 h later by semiquantitative RT–PCR and Western blotting. N3-
IC-transfected 2017 cells displayed significantly increased expression of IK-dn
isoforms (compared with untransfected or empty vector-transfected controls) at
both the mRNA (Figure 4A, upper right panel) and protein (Figure 4B, right
panel) levels, but there was no evidence of these isoforms in transfected M31
cells (Figure 4A, lower panels). The shift toward IK-dn expression seems to be a
Notch3-specific effect as it was not observed after transient transfection of 2017
or M31 cells with Notch1-IC (Figure 4, left panels). Noteworthily, Notch1-IC
was able to increase the expression of Hes-1 and Deltex in transfected 2017 cells
(Figure 4A, upper left panels).
Moreover, it was able to increase the Hes-1 promoter activity in a luciferase
reporter assay to a greater extent than Notch3-IC in both HEK293 and M31 cells
(Supplementary Figure 3). We finally addressed the possible effect of
exogenous Notch1-IC on the expression of Notch3 in 2017 cells. The middle
panel of Figure 4A shows that enforced expression of exogenous Notch1-IC
does not modify the endogenous Notch3 expression of 2017 cells.
Collectively, the findings presented thus far indicate that activated Notch3
signaling in the presence of pre-TCR expression can modulate IK isoform
expression profiles in vivo and in vitro. This effect, which appears to be Notch3-
specific, could thus be responsible (at least in part) for the abnormal expression
of IK-dn isoforms in premalignant and malignant thymocytes of Notch3–IC tg
mice.
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Notch3 and IK act cooperatively to regulate pTα gene expression
The findings described above, together with a recent report that loss of IK
function leads to increased expression of Notch3 and pTα  in murine T
lymphoma cells170suggest the possibility of direct crosstalk between Notch3 and
IK that serves to regulate pTα gene transcription.
Previous studies have shown that the pTα enhancer is activated by Notch1
signaling via CSL-binding sites,49 and we have demonstrated dose-dependent
activation of the pTα  promoter by Notch3.222To further elucidate the
mechanisms underlying the effects of Notch3 on the regulatory region of pTα,
we transfected non-lymphoid HEK293 cells with a luciferase reporter construct
containing the entire pTα  promoter sequence (as reported in GenBank,
accession number U27268). Enforced coexpression in these cells of N3-IC and
Mastermind (MAM), the positive regulator of Notch activity, increased pTα
promoter activity about 10-fold, and additional increases were observed after the
addition of RBP-Jk/CSL (Figure 5 and not shown). Although the ability of
Notch-IC to activate transcription is known to be potentiated by its interaction
with these coactivators,39,40,43 this is the first demonstration that Notch3-IC-
driven activation of the pTα regulatory element is significantly enhanced by a
transcriptional complex composed of RBP-Jk/CSL and MAM.
Full-length DNA-binding IK isoforms have been shown to repress CSL-
dependent Notch-triggered transcriptional activity, and this effect is attenuated
by the coexpression of alternatively spliced IK-dn isoforms.169 Similarly,
enforced expression of the IK-1 isoform in HEK 293 cells significantly inhibited
activation of the pTα promoter triggered by the Notch3 and coactivator complex
(Figure 5A), but there was no evidence of transcriptional repression in cells
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transfected with the dominant-negative IK-6 alone (Figure 5A). In the presence
of a constant level of coexpressed IK-1, the increasing presence of IK-6
progressively diminished and ultimately overcame the transcriptional repression
induced by the full-length isoform, restoring pTα promoter activation to levels
similar to those produced by the Notch3-dependent transcriptional complex in
the absence of IK (Figure 5A). This body of evidence strongly suggests that
Notch3 regulates the alternative splicing of IK and that, in so doing, it modulates
its own ability to induce transcriptional activation of pTα. It remained to be seen
how the Notch3-triggered complex interacts with the pTα promoter region and
what is the basis for IK antagonism. Our analysis revealed that the pTα
promoter contains a canonical consensus CSL-binding sequence, several
consensus sequences that are specific for IK and three TGGGAA motifs
corresponding to the RBP-Jk/CSL core sequence. The latter finding was
particularly interesting as this same core sequence is also present in the
consensus DNA-binding sequences of IK.131,169The three motifs were desig-
nated CSL-core 1, CSL-core 2 and CSL-core 3 in accordance with their
positions in the pTa promoter (485, 200 and –149 bp, respectively) (Figure 5B).
The pTα promoter region containing the three motifs was cloned and to evaluate
their possible roles in Notch3-dependent transcriptional activation, we generated
two luciferase reporter constructs, one (CSL-Mut1) with a specific mutation in
CSL-core1 and the second (CSL-Mut2/3) with mutations in CSL-core2 and
CSL-core3 (Figure 5B), and transfected them, together with N3-IC and its
coactivators, into HEK293 cells. In cells expressing the CSL-Mut2/3, luciferase
activity was similar to that observed with
the wt sequence, but CSL-Mut1 expression was associated with drastically
reduced activity (Figure 5C). These findings indicate that the TGGGAA
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sequence at 485 bp is necessary for Notch3-dependent transcriptional activation
of pTα.
In order to study the basis for Notch3 and IK-1 antagonism on pTα
transcriptional activation, we first examined the ability of both IK-1 and CSL to
bind the same site of pTα regulatory sequence by using the CSL wt sequence of
the pTα promoter in an electrophoretic mobility shift assay (EMSA). We
observed that both the IK-1 and CSL proteins, obtained from nuclear extracts
derived from COS cells transfected with
either IK-1 or CSL expression vectors, were able to bind the same site. We used
as probe an oligo containing the wt CSL-core1 consensus (TGGGAA) of the
pTα promoter, as indicated in Figure 5B. The interactions of IK-1 and CSL with
the oligo were specific, as they were able to be competed with 100-fold molar
excess of the unlabeled CSL-wt, but not with 100-fold molar excess of
unlabeled mutant oligo CSL-MUT 1 (Figure 5D).
Moreover, the luciferase reporter and EMSA assays were confirmed in Notch3-
IC transiently transfected 2017 cells by evaluating the ability of Notch3-IC to
induce an increase in endogenous pTα expression and demonstrating that this
induction is repressed by IK-1 and derepressed by IK-6 (Figure 5E). Finally, to
address whether IK and CSL truly compete in vivo for the same candidate site in
the pTα promoter, we performed chromatin immunoprecipitation (ChIP)
experiments using primary thymocytes derived from wt and N3-ICtg mice.
Figure 5F (right panel) shows that both CSL and IK proteins are associated with
the pTα promoter in chromatin extracts derived from wt thymocytes. In contrast,
CSL but not IK antibodies efficiently recovered the pTα promoter fragment
using chromatin extracts derived from N3-ICtg mice. These results demonstrate
that CSL and IK directly associate at the same binding site in the pTα promoter
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and might explain the functional collaboration observed between Notch3 and the
IK-dn isoforms in sustaining pTα expression, finally supporting the hypothesis
that the increased amount of IK-dn isoforms in thymocytes of N3-ICtg mice
prevents the DNA binding of IK, thus allowing the derepression of pTα
expression.
The effects of Notch3 on the expression of IK spliced variants depend on
pre-TCR-dependent upregulation of the RNA-binding protein HuD
Next, we attempted to identify mechanisms specifically triggered by Notch3 that
would account for the presence of alternatively spliced IK isoforms. In a recent
Affymetrix MAS 5.0 microarray analysis of the global gene expression profile
of N3-ICtg premalignant thymocytes (results currently unpublished), we
discovered a striking increase (about 39-fold compared with wt controls from 2-
week-old mice) of mRNA for HuD, an RNA-binding protein of the ELAV/Hu
family,184which is reportedly capable of regulating both the stability178,193,195 ,
and the alternative splicing212,215 of RNA. In the present study, we confirmed, by
means of semiquantitative RT–PCR the presence of significantly increased HuD
mRNA levels in DN and DP thymocytes from N3-ICtg mice (Figure 6A). Even
more interesting was our finding that Notch3-induced enhancement of HuD
expression is pre-TCR dependent. In fact, in contrast to wt and N3-ICtg
thymocytes, cells from both Notch3-IC/pTα/ and pTα/ mice displayed HuD
expression levels that were virtually undetectable in both DN and DP cells
(Figure 6A). In addition, HuD expression was dose-dependently upregulated in
the pre-T cell line 2017 after transient transfection with increasing amounts of
Notch3-IC (Figure 6B, left panel), but no increases were observed in transfected
M31 cells (not shown). The negative results observed when transfections were
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carried out with Notch1-IC (Figure 6B, right panel) indicate that the
upregulation of HuD is a Notch3-specific effect.
Collectively, these results strongly suggest that the Notch3-induced upregulation
of HuD expression, which is pre-TCR- dependent, may be related to the
increased generation and/or enhanced stability of IK-dn isoforms. As a putative
down-stream effector of pre-TCR signaling, HuD expression alone would be
expected to allow the shift toward IK-dn isoform expression even in the absence
of pre-TCR. This hypothesis was confirmed when we transiently transfected
2017 and M31 cells with a pcDNA3 expression vector containing cloned HuD.
In both cell lines, increasing amounts of transfected HuD elicited progressive
increases in short IK-dn isoforms, an effect that was unrelated to the
differentiation stage or to pre-TCR expression (Figure 6C). Together, the above
results suggest that HuD protein mediates the effect of Notch3 on the differential
expression of IK isoforms. In order to directly address this issue, we performed
siRNA experiment to study the effect of HuD silencing on the Notch3-induced
modulation of IK-dn isoforms. Figure 6D shows that the silencing of HuD
abrogates the effect of Notch3 on IK isoform modulation. We also show the
reverse by silencing endogenous Notch3. Indeed, Figure 6E shows that the
siRNA of Notch3 is able to inhibit the constitutive expression of HuD in 2017
cells. It remained to be seen whether the HuD-increased expression and the shift
toward IK-dn isoforms were induced by endogenous Notch signaling. As shown
in Supplementary Figure 2, 2017 cells constitutively express endogenous pTα,
Notch3 and Notch1, whereas M31 cells express similar levels of Notch1, but
very low levels of Notch3 and undetectable pTα when compared with 2017.
Thus, we performed coculture experiments of 2017 cells on OP9 stromal cells
that have been described to constitutively express the Notch ligand Jagged-1 at
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levels similar to those of normal thymic epithelial cells and to be able to trigger
endogenous Notch signaling.85,223
We observed that the coculture with OP9 cells induced the same effect on HuD
and IK-dn isoform expression as the transfection of Notch3-IC, and when the g-
secretase inhibitor I was added to the culture medium the effect was inhibited,
thus demonstrating that it was due to the triggering of endogenous Notch
signaling (Figure 6F).
The RNA-binding protein HuD is expressed in human T-ALL
Whereas the expression of alternatively spliced IK isoforms has been previously
reported in several human leukemias,163,165-166 HuD expression was not addressed
before. The observations reported above prompted us to analyze HuD mRNA
expression in human T-ALL, as well as the possible role of HuD and Notch3 in
regulating the IK isoform expression pattern. We utilized the previously
described human T-ALL cell line Molt-3.165 Figure 7A shows that this cell line,
similar to the mouse 2017 cell line, constitutively expresses Notch1 and 3, HuD,
both the pTa isoforms a and b and an altered IK isoform profile. In order to
address directly the relationships between Notch, HuD and IK isoforms in
human T-ALL, we performed siRNA experiments in Molt-3 cells. Figure 7B
shows that knockdown of Notch3 and HuD but not of Notch1 is able to alter the
IK isoform profile displayed by Molt-3 cells.
Interestingly, besides specifically affecting the pattern of IK isoform expression,
the knockdown of Notch3 results in a higher inhibition of proliferation of Molt-3
cells when compared with the knockdown of Notch1 (49 versus 30%) (Figure
7C). Finally, we studied four different primary human T-ALLs and one primary
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B-ALL utilizing bone marrow samples from patients at different stages of
disease (exordium and remission) and one control patient. We observed
expression of HuD in all of the T-ALL exordium samples; in contrast, HuD
expression was undetectable in all the samples of the same patients in remission
stage, in the sample from the B-ALL-bearing patient and in the control (Figure
7D).
DISCUSSION
Pre-TCR expression is indispensable for the early steps of T-cell differentiation
and for progression of Notch3-dependent T-cell leukemia.74,217 The pTα gene
encodes an essential pre-TCR component and is a key target of Notch3
signaling, which strongly en- hances pTα promoter transcription through the
formation of an activator complex composed of N3-IC, CSL and MAM. Our
findings argue that the hematopoietic cell-specific transcription repressor, IK, is
an important regulator of Notch3’s effects on pTα. The pTα promoter region
contains three consensus DNA-binding TGGGAA sequences that are recognized
by both IK and the Notch effector protein CSL, and one of these was shown to
be essential for Notch3-induced activation of pTα. This activation is inhibited
by DNA-binding IK isoforms, but our findings indicate that, in the presence of a
functional pre-TCR complex, Notch3 can eliminate this restraint by increasing
the expression of IK-dn splice variants that are incapable of DNA binding. It
appears, therefore, that, in addition to the direct effect exerted by its activator
complex, Notch3 signaling also enhances pTa transcription indirectly by
diminishing the transcription-repressing activity of IK. The effect of Notch3 on
IK isoform expression seems to be mediated, at least in part, by the RNA-
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binding protein, HuD. The highly conserved Hu proteins (and HuD in particular)
play critical roles in the post-transcriptional modulation of gene expression,
ranging from regulation of alternative splicing and translation to modulation of
mRNA transport and stability.178,193,195 HuD has long been known as one of the
earliest markers of neural differentiation,187 and more recently it has also been
described in the CD34 _ subset of bone marrow cells,208 but our findings are the
first evidence of its expression by mouse thymocytes and, more importantly, in
human T-ALL. Whereas low levels were observed in wt DP thymocytes, DN
and DP thymocytes from N3-ICtg mice display high levels of HuD expression.
Moreover, N3-IC transfection resulted in significantly increased dose-dependent
expression of HuD. Even more intriguing was the correlation observed between
this upregulation of HuD (which wasstrictly pre-TCR-dependent in vivo and in
vitro) and the shift toward increased generation of IK-dn isoforms in cells.
The fact that the same shift was also observed following transfection of HuD
alone, independently of pre-TCR presence, being instead inhibited by siRNA-
induced silencing of endogenous HuD, adds further support to the view that this
protein plays a direct role in Notch3’s modulation of IK isoform expression
patterns. Moreover, the decreased expression of HuD following the knockdown
of endogenous Notch3 by siRNA and its increased expression observed after
coculturing 2017 cells on Jagged-1-expressing OP9 cells, inhibited by the
treatment with GSI, suggest that HuD expression is induced by and depends on
the triggering of endogenous Notch signaling. The virtual absence of IK-dn
isoforms in N3-IC/pTα–/– double mutant thymocytes was accompanied by a
decrease in IK-1 and IK-2/3 transcripts as well (with respect to levels found in
N3-ICtg, pTα–/– and wt cells). This finding suggests that the absence of HuD
might also affect IK expression at a pre-mRNA level. More intriguingly, the
observation that HuD is not expressed in the absence of pTα, independently of
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the overexpression of Notch3, suggests that Notch signaling alone, in the
absence of pTα , is not sufficient in sustaining HuD expression. Reduced
expression of IK-1 and 2/3, by decreasing the inhibitory role of IK DNA-
binding isoforms, could conceivably potentiate Notch3 activity and favor the
activation of  Notch target genes other than pTα, and an effect of this type might
explain Notch3’s partial reversal of the developmental arrest that characterizes
thymocytes from pTα–/– single mutant mice.74 IK target/binding sites have also
been reported in the enhancer region of CD3 and CD4 genes.19
In conclusion, we provide evidence for a novel non-redundant mechanism
whereby Notch3 and the hematopoietic nuclear factor IK cooperate in the
regulation of T-cell development and lymphomagenesis. The molecular model
portrayed by our findings (Figure 8) is characterized by crosstalk among
Notch3, IK and the pTα/pre-TCR signaling activity that is mediated in part by
the RNA-binding protein HuD. Its pre-TCR-dependent upregulation,
specifically induced by Notch3, diminishes the IK- induced repression of
transcriptional activation of pTa, an effect that appears to be related to
regulation of the differential splicing and/or the stability of IK mRNAs. This is
the first evidence that the RNA-binding protein HuD plays a role in the complex
scenarios of T-cell differentiation and tumorigenesis.
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FIG.1 Alternatively spliced Ikaros (IK) isoforms are overexpressed in pre-malignant
thymocytes from Notch3-IC transgenic (N3-ICtg) mice.
(A) CD4+ and CD8+ subset distributions (documented by two-color FCA) of thymocytes from
2-week-old wild -type (wt) and N3-ICtg mice. The number in each quadrant indicates the
percentage of total cells represented by the corresponding subset.
(B) IK isoform expression profiles assessed by RT-PCR (upper panel) and Western blot
(lower panel) analysis of whole-thymocyte lysates from two wt and two N3-ICtg mice.  IK1
and IK2/3: DNA-binding IK isoforms; IK-dn: Dominant negative IK splice variants incapable
of DNA binding. PCR products were analyzed by Southern blot using IK-6 cDNA as probe to
detect the specific sequences. mRNA expression was monitored along the exponential phase
of amplification and normalized to β-actin (β-act). In Western blot assay results were
normalized to β-tubulin (β-tub). The data are representative of three similar experiments.
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FIG.2  Ikaros (IK) isoform expression patterns are altered in T lymphoma cells from
Notch3-IC transgenic (N3-ICtg) mice.
 (A) Two-color-FCA analysis of CD4 vs CD8 expression in freshly isolated thymocytes
(THY) (upper panels) and lymph-node cells (LN) (lower panels) from 5-week-old mice: two
wild-type (wt1 and wt2) and two N3-ICtg (N3-ICtg3 and N3-ICtg4). The number in each
quadrant indicates the percentage of total cells represented by the corresponding subset.
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(B) (B) Immunoblots of whole-cell extracts from the cells shown in panels A. IK1 and IK2/3:
DNA-binding Ikaros isoforms; IK-dn: Dominant negative Ikaros isoforms incapable of DNA-
binding.
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FIG.3 Ikaros (IK) isoform expression patterns in thymocyte depend on pTa expression.
(A) RT-PCR analysis of IK isoform expression was performed on RNA from sorted CD4-
CD8- double negative (DN) and CD4+CD8+ double positive (DP) thymocytes from wild-type
(wt), Notch3-IC transgenic (N3-ICtg), Notch3-IC/pTα-/-  and p Tα -/-  mice. (B) Ikaros
immunoblot of whole-cell lysates of unfractionated thymocytes from one wt mouse and two
mice of each of the three mutant genotypes listed above.  IK1 and IK2/3: DNA-binding Ikaros
isoforms; IK-dn: Dominant negative Ikaros isoforms incapable of DNA-binding. IK ex 7:
Ikaros exon 7. Results were normalized to  β-tubulin (β-tub).
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FIG.4 Notch3 regulates alternative splicing of Ikaros (IK) in vitro.
DN1 and DN3 thymocytes (represented respectively by the M31 and 2017 cell
lines were transfected with increasing amounts of Notch3 (right upper and lower
panels) or Notch1 (left upper and lower panels), and Ikaros mRNA and protein
expression was assessed by RT-PCR. Hes-1 and Deltex RNA expression were
used as control of correct function of Notch1-IC and Notch3-IC constructs,
while Notch3 RNA expression confirms the specific role of Notch3 with respect
of Notch1 in increasing expression of Notch3  (A) and Western blotting (B). IK1
and IK2/3: DNA-binding IK isoforms; IK-dn: Dominant negative IK isoforms
incapable of DNA-binding. β-actin (β-act) and β-tubulin (β-tub) are shown as
controls of equivalent loading of each sample
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FIG.5 Transcriptional activation of the pTα promoter by Notch3 is differentially
regulated by Ikaros isoforms.
CSL-MUT 2/3
CSL-MUT 1actaggctTaGtAcaggcttt------aagcactTGGGAActagagg--------tgtgatcTGGGAAgcagtgttgatccgaAtCaTgtccgaaa ------ttcgtgaACCCTTgatctcc----------acactagACCCTTcgtcaca
actaggctTGGGAAaggcttt ------aagcactTaGtAcctagagg--------tgtgatcTaGtAcgcagtgt
tgatccgaACCCTTtccgaaa ------ttcgtgaAtCaTggatctcc----------acactagAtCaTgcgtcaca
actaggctTGGGAAaggcttt------aagcacTGGGAActagggg--------tgtgatcTGGGAAgcagtgt
tgatccgaACCCTTtccgaaa--------ttcgtgACCCTTgatcccc----------acactagACCCTTcgtcaca
CSL wt
CSL-core1 CSL-core2 CSL-core3
-149bp-485bp -200bp
pT
al
ph
a-
ac
tiv
ity
 (f
ol
d 
in
du
ct
io
n)
PCDNA3
RBP -Jκ         
MAM             
NOTCH3       
CSLWT        
CSL- MUT 1   
CSL-MUT 2/3
2
4
6
8
0
1
2
3
4
5
6
7
8
9
0
+
-
-
-
-
-
-
-
+
+
+
+
-
-
-
+
+
+
-
+
-
-
+
+
+
-
-
+
B)
C)
A)
PCDNA3    +  -   -      -  -   -   -     -   -   -       -  -   -
RBP -Jκ       -  -   -     + +  +  +    +  +  +      + +  +
MAM           -   -   -     + +  +  +    +  +  +      + +  +
NOTCH3     -  -   -      + +  +  +    +  +  +      + +  +
IK1              -  -   +      - +  +  +     +  +  +      -  -  -
IK6               -  +   -     -  -   -  -     +  +  +     +  +  +
IK1 IK6 IK6
0
4
8
12
16
pT
al
ph
a-
ac
tiv
ity
 (f
ol
d 
in
du
ct
io
n)
D)
- PC
DN
A3
Comp:
IK-1 CSL
Probe:
wtm
ut
wt m
ut- -
CSL wt
Extr:
E)
CSLIgG Ikaros Input
W
T
N3
-tg
W
T
N3
-tg
W
T
N3
-tg
W
T N3
-tg
ChIP
 -602 bp                          -227 bp
pTα promoter
Not
ch3
-IC
Not
ch3
-IC+
Ik1
Not
ch3
-IC+
Ik1+
Ik6
PCD
NA
3
pTαa
pTαb
2017 cells
β-act
Not
ch3
-IC
Not
ch3
-IC+
Ik1
Not
ch3
-IC+
Ik1+
Ik6
PCD
NA
3
  O
D
0
1
2
3
pTαa
pTαb
F)
73
HEK 293 cells were transfected with a luciferase reporter construct containing the pTα
promoter together with Notch3, RBP-Jκ, and Mastermind (MAM). A) The pTα promoter is
activated by the Notch3 transcription activator complex (Notch3+RBP-Jκ+MAM). Increasing
amounts of IK-1 alone (200-800 ng) dose-dependently repressed Notch3-driven transcription
of the pTα promoter, but the non-DNA-binding IK6-dn isoform alone (200-800ng) had no
impact.  When IK-1 and IK-6 were co-transfected, increasing amounts of IK-6 progressively
diminished the transcription repression induced by fixed amount of IK-1. DNA contents in the
different transfection assays were normalized with empty vector (pcDNA3). The data shown
were collected from three independent experiments; vertical bars indicate standard deviation.
(B) Mutational analysis of the TGGGAA core sequence in the pTα promoter. Wild-type and
mutated sequences from the entire promoter are shown in bold-face type, and the cloned CSL
wt sequence and mutant constructs, CSL1MUT and CSL2MUT+CSL3MUT, are shown. (C)
Luciferase activity of wild-type and mutant pTα promoter constructs. pCDNA3: empty
vector. The histograms represent mean results of three independent transfection experiments.
Vertical bars indicate the range of standard errors. (D) EMSA: both the Ik1 and CSL protein,
obtained from nuclear extracts derived from COS cells transfected with either Ik-1 or CSL
expression vectors. We used as a probe an oligo containing the wild type CSL-core1
consensus (TGGGAA) as indicated in the panel B of revised figure 5. For competition
(comp), 100 fold molar excess of cold CSL-wt or CSL-MUT 1 was used. (E) 2017 cells were
used in transient transfection experiments to evaluate the ability of Notch3-IC to induce
increased pTalpha expression and to demonstrate that this induction is repressed by Ik-1 and
derepressed by Ik-6.
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FIG.6 Notch3-induced skewing of Ikaros (IK) isoform profiles depends on Notch3-
dependent upregulation of the RNA-binding protein, HuD.
HuD expression was assessed by semiquantitative RT-PCR analysis of RNA from (A) sorted
CD4-CD8- double-negative (DN) and CD4+CD8+ double-positive (DP) thymocytes from wt,
N3-ICtg,  N3-ICtg /pTα-/-   and pTα-/-    mice;  and (B) DN-3 thymocytes of the 2017 line
transfected with increasing amounts of Notch3 (left panel) or Notch1 (right panel).  (C) RT-
PCR detected expression of alternatively spliced IK isoforms in DN-3 and DN-1 thymocytes
(2017 and M31 cell lines, respectively) transfected directly with HuD. (0= non-transfected
cells; pCDNA3=empty vector-transfected cells). (D) siRNA experiment to study the effect of
HuD silencing on the Notch3-induced modulation of IK-dn isoforms. (E) siRNA of Notch3 is
able to inhibit the constitutive expression of HuD in 2017 cells. (F) Coculture experiment of
2017 cells on OP9 stromal cells expressing the Notch ligand Delta-like 1 (OP9-DL1) or
parental OP9 cells, expressing Notch ligands Jagged-1 and Jagged-2. GSI: γ-secretase
inhibitor; IK-1 and IK-2/3: DNA-binding IK isoforms; IK-dn: Dominant negative IK isoforms
incapable of DNA-binding. mRNA expression was monitored along the exponential phase of
amplification and normalized to β-actin (β-act).
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Figure 7 The RNA-binding protein HuD is expressed in human T-ALL and regulates IK
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isoform profile.
 (A) RT–PCR expression analysis of human Notch1, Notch3, HuD, IK and pTa mRNAs in
Molt-3 cell line and peripheral T lymphocytes from one healthy donor (PTL) used as control.
Results were normalized to b-actin (b-act). (B) siRNA assay showing that HuD and Notch3,
but not Notch1, are able to regulate IK mRNA expression profile in Molt-3 cells, as assessed
by RT–PCR; CTR siRNA: scrambled siRNA. (C) Inhibition of proliferation of Molt-3 cells.
Recovery of Molt-3 cells after Notch3, HuD, Notch1 or scrambled siRNA transfection,
compared to the cell number at the starting point (hatched bars). The data shown represent the
average of three independent experiments; vertical bars indicate standard deviation. (D) HuD
expression was assessed by semiquantitative RT–PCR analysis of RNA in bone marrow
samples from four different primary human T-ALLs and
one primary B-ALL at different stages of disease (exordium, EX; and remission, REM) and
one control patient (CTR). Results were normalized to b-actin (b-act).
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FIG. 8  Cross-talk among Notch3, Ikaros, and pre-TCR in the regulation of T-cell
development and lymphomagenesis.
Overexpression of HuD by thymocytes is triggered in a pre-TCR-dependent manner by the
activation of Notch3 signalling.  As a result of its modulating effects on the splicing and/or
stability of Ikaros mRNA, HuD in turn promotes the preferential expression of IK-dn
isoforms, which diminish IK-induced transcriptional repression and further enhance the
upregulation of pTα gene expression induced directly by the Notch3-CSL transcription
activator complex.
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